<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancers (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Cancers (Basel)</journal-id><journal-id journal-id-type="publisher-id">cancers</journal-id><journal-title-group><journal-title>Cancers</journal-title></journal-title-group><issn pub-type="epub">2072-6694</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29799499</article-id><article-id pub-id-type="pmc">6025274</article-id><article-id pub-id-type="doi">10.3390/cancers10060161</article-id><article-id pub-id-type="publisher-id">cancers-10-00161</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>KLF10 as a Tumor Suppressor Gene and Its TGF-&#x003b2; Signaling</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4971-6283</contrib-id><name><surname>Memon</surname><given-names>Azra</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Woon Kyu</given-names></name><xref rid="c1-cancers-10-00161" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-cancers-10-00161">Laboratory of Developmental Genetics, Department of Biomedical Sciences, School of Medicine, Inha University, Incheon 22212, Korea; <email>azrabiochem@yahoo.com</email></aff><author-notes><corresp id="c1-cancers-10-00161"><label>*</label>Correspondence: <email>wklee@inha.ac.kr</email>; Tel.: +82-32-860-9882; Fax: +82-32-860-9818</corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>5</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2018</year></pub-date><volume>10</volume><issue>6</issue><elocation-id>161</elocation-id><history><date date-type="received"><day>25</day><month>4</month><year>2018</year></date><date date-type="accepted"><day>23</day><month>5</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 by the authors.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Kr&#x000fc;ppel-like factor 10 (KLF10), originally named TGF-&#x003b2; (Transforming growth factor beta) inducible early gene 1 (TIEG1), is a DNA-binding transcriptional regulator containing a triple C2H2 zinc finger domain. By binding to Sp1 (specificity protein 1) sites on the DNA and interactions with other regulatory transcription factors, KLF10 encourages and suppresses the expression of multiple genes in many cell types. Many studies have investigated its signaling cascade, but other than the TGF-&#x003b2;/Smad signaling pathway, these are still not clear. KLF10 plays a role in proliferation, differentiation as well as apoptosis, just like other members of the SP (specificity proteins)/KLF (Kr&#x000fc;ppel-like Factors). Recently, several studies reported that KLF10 KO (Knock out) is associated with defects in cell and organs such as osteopenia, abnormal tendon or cardiac hypertrophy. Since KLF10 was first discovered, several studies have defined its role in cancer as a tumor suppressor. KLF10 demonstrate anti-proliferative effects and induce apoptosis in various carcinoma cells including pancreatic cancer, leukemia, and osteoporosis. Collectively, these data indicate that KLF10 plays a significant role in various biological processes and diseases, but its role in cancer is still unclear. Therefore, this review was conducted to describe and discuss the role and function of KLF10 in diseases, including cancer, with a special emphasis on its signaling with TGF-&#x003b2;.</p></abstract><kwd-group><kwd>KLF10</kwd><kwd>TGF-&#x003b2;</kwd><kwd>disease</kwd><kwd>cancer</kwd><kwd>tumor suppressor</kwd></kwd-group></article-meta></front><body><sec id="sec1-cancers-10-00161"><title>1. SP/KLF Family</title><p>Transcription factors SP (specificity proteins) and KLF (Kr&#x000fc;ppel-like Factors) contain three Kr&#x000fc;ppel-like zinc fingers collectively known as the SP/KLF family. While members of this family also have a unique amino-terminal (N-terminal) end that acts as the functional domain and that allows it to bind specifically to a certain partner, the N-terminal domains of the various KLFs vary, and these different domains mediate different molecular functions [<xref rid="B1-cancers-10-00161" ref-type="bibr">1</xref>]. In the early 1980s, SP1 was first identified as a protein capable of binding GC and GT rich regions or the 5&#x02032;-CACCC-3&#x02032; DNA sequence in the SV40 promoter, indicating that it could serve as a transcriptional regulator [<xref rid="B2-cancers-10-00161" ref-type="bibr">2</xref>]. To date, a total of 27 identified members in mammals (human) have been characterized, from which nine members of the SP subfamily (SP1&#x02013;SP9) and 18 members of the KLF family (KLF1&#x02013;KLF18) were included (<xref rid="cancers-10-00161-t001" ref-type="table">Table 1</xref>) [<xref rid="B3-cancers-10-00161" ref-type="bibr">3</xref>,<xref rid="B4-cancers-10-00161" ref-type="bibr">4</xref>,<xref rid="B5-cancers-10-00161" ref-type="bibr">5</xref>]. They were categorized as members of SP/KLF because of their resemblance in the zinc finger motif located toward the C-terminus [<xref rid="B6-cancers-10-00161" ref-type="bibr">6</xref>]. Buttonhead (Btd) box domain CXCPXC, which differentiate SP from KLFs is only present in the SP family at just 5&#x02032; of the KLF DNA binding domain [<xref rid="B7-cancers-10-00161" ref-type="bibr">7</xref>], whereas N-terminal regions of KLF/SP transcription factors are extremely flexible and consist of different combinations of transactivation/repression domains.</p><p>SP/KLF factors have been found to be engaged in fundamental cell processes such as growth, differentiation, apoptosis, and angiogenesis; therefore, the family is involved in numerous aspects of tumorigenesis, while other diseases behave as either activators or repressors (<xref rid="cancers-10-00161-t001" ref-type="table">Table 1</xref>). Mammalian KLFs have been divided into 3 groups based on the shared domain. Most of the members of this family are widely expressed, but some have restricted tissue expression. Formerly these KLFs were named as they were identified, KLF10 and KLF11 were originally identified as early genes induced by transforming growth factor &#x003b2; and were named TGF-&#x003b2; inducible early gene 1 (TIEG1) and TGF-&#x003b2; inducible early gene 2 (TIEG2), respectively [<xref rid="B8-cancers-10-00161" ref-type="bibr">8</xref>,<xref rid="B9-cancers-10-00161" ref-type="bibr">9</xref>]. Conversely, KLF1 expressed in specific tissues erythroid and therefore referred to as EKLF [<xref rid="B6-cancers-10-00161" ref-type="bibr">6</xref>], KLF2 is found in the lung and therefore referred to as LKLF [<xref rid="B10-cancers-10-00161" ref-type="bibr">10</xref>], KLF3 is widely expressed and therefore called basic BKLF [<xref rid="B11-cancers-10-00161" ref-type="bibr">11</xref>], KLF4 is initially found gut enriched KLF and called GKLF [<xref rid="B12-cancers-10-00161" ref-type="bibr">12</xref>,<xref rid="B13-cancers-10-00161" ref-type="bibr">13</xref>], KLF5 is found in the intestines and therefore known as IKLF [<xref rid="B14-cancers-10-00161" ref-type="bibr">14</xref>], and KLF15 is initially found in the kidney so it is referred to as KKLF. KLF9 was identified as a basal transcription element binding (BTEB) protein [<xref rid="B13-cancers-10-00161" ref-type="bibr">13</xref>], with KLF5 and KLF13 as homologs (BTEB2 and BTEB3, respectively) [<xref rid="B15-cancers-10-00161" ref-type="bibr">15</xref>], while KLF17 was first discovered as a germ cell-specific gene encoding a zinc finger protein 393 (Zfp393) [<xref rid="B16-cancers-10-00161" ref-type="bibr">16</xref>]. KLF18 genes/pseudogenes are found in most placental mammals (for example, human, mouse) [<xref rid="B3-cancers-10-00161" ref-type="bibr">3</xref>].</p><p>The key feature of SP/KLF proteins is the presence of a DNA-binding domain consisting of three Kr&#x000fc;ppel-like zinc fingers classified into different subfamilies based on the presence of conserved motifs within their N-terminal domains outside the zinc finger domain (<xref ref-type="fig" rid="cancers-10-00161-f001">Figure 1</xref>). KLF members are divided into distinct groups according to functional similarities revealed upon structural analysis (reviewed in ref [<xref rid="B17-cancers-10-00161" ref-type="bibr">17</xref>]. Most KLF proteins were randomly named by their discoverers, which led to the development of a new nomenclature by the HGNC (Human Gene Nomenclature Committee) that serially designates each KLF protein by number [<xref rid="B18-cancers-10-00161" ref-type="bibr">18</xref>].</p><p>Several groups have described various approaches to identify all of the members of the SP/KLF family in human and mouse genomes, and the effects of these proteins in more detail [<xref rid="B4-cancers-10-00161" ref-type="bibr">4</xref>,<xref rid="B19-cancers-10-00161" ref-type="bibr">19</xref>,<xref rid="B20-cancers-10-00161" ref-type="bibr">20</xref>,<xref rid="B21-cancers-10-00161" ref-type="bibr">21</xref>,<xref rid="B22-cancers-10-00161" ref-type="bibr">22</xref>,<xref rid="B23-cancers-10-00161" ref-type="bibr">23</xref>,<xref rid="B24-cancers-10-00161" ref-type="bibr">24</xref>,<xref rid="B25-cancers-10-00161" ref-type="bibr">25</xref>]. As shown in <xref ref-type="fig" rid="cancers-10-00161-f001">Figure 1</xref>, the protein-binding domains within the protein structures of KLF Group 1 (KLF 3, 8, and 12) serve as transcriptional repressors through their interaction with the C-terminal binding protein (CtBP). Group 2 (KLF 1, 2, 4, 5, 6, and 7) function mostly as transcriptional activators and bind to histone acetyltransferases (HATs) and Group 3 (KLF 9, 10, 11, 13, 14, and 16) have repressor activity through the presence of a Sin3A-binding site. KLF 15, 17 and 18 based s contain no defined protein interaction motifs. Eighteen mammalian KLFs have been recognized to date, and these have received increased attention because of their basic, diverse biological processes and their contributions to human diseases (<xref rid="cancers-10-00161-t001" ref-type="table">Table 1</xref>). Here, we reviewed KLF10 to understand its role and function in diseases, including cancer as a tumor suppressor, as well as its interaction with TGF-&#x003b2; signaling.</p></sec><sec id="sec2-cancers-10-00161"><title>2. KLF10 Induced Mechanism of Gene Activation</title><p>Transforming growth factor (TGF&#x003b2;) beta-like group proteins consist of a large family of related growth factors comprised of at least 30 members in mammals. TGF&#x003b2; has three isoform TGF&#x003b2;1, 2, 3 which function as primary mediators of TGF&#x003b2; signaling. These three ligands are structurally related to activins, nodals and some growth and differentiation factors (GDFs), and the bone morphogenetic proteins (BMP) [<xref rid="B26-cancers-10-00161" ref-type="bibr">26</xref>]. TGF&#x003b2; superfamily members regulate fundamental cell processes such as proliferation, differentiation, death, cytoskeletal organization, adhesion, and migration. Smad proteins are the major intracellular mediators of TGF&#x003b2; signaling pathway to control transcription of their target genes [<xref rid="B27-cancers-10-00161" ref-type="bibr">27</xref>]. TGF-&#x003b2;1 activates SMAD-dependent and -independent pathways to exhibit its biological activities [<xref rid="B28-cancers-10-00161" ref-type="bibr">28</xref>]. Members of the SMAD are classified into three groups, R-SMADs, the receptor-regulated SMADs which include SMAD1, SMAD2, SMAD3, SMAD5, and SMAD8, Co-SMAD (common SMAD) which have only one member SMAD4, I-SMADs (inhibitory SMADs) including SMAD6 and SMAD7. It is well-known that TGF-&#x003b2; is stimulated by activating downstream mediators SMAD2 and SMAD3, and is negatively regulated by an inhibitory SMAD7 [<xref rid="B29-cancers-10-00161" ref-type="bibr">29</xref>].</p><p>In addition, several KLFs are linked to TGF&#x003b2; signaling, TGF&#x003b2; induces the expression of early response transcription factors such as the Sp1/KLF like zinc-finger proteins KLF10 and KLF11 [<xref rid="B9-cancers-10-00161" ref-type="bibr">9</xref>,<xref rid="B30-cancers-10-00161" ref-type="bibr">30</xref>]. KLF10, which work as effector proteins in TGF&#x003b2; mediated cell growth control and differentiation were originally defined as TGF-&#x003b2; inducible early gene 1 (TIEG1) in human osteoblast (OB) cells [<xref rid="B10-cancers-10-00161" ref-type="bibr">10</xref>]. The KLF10 N-terminal protein segments also contain three unique repression domains, R1, R2, and R3 [<xref rid="B10-cancers-10-00161" ref-type="bibr">10</xref>,<xref rid="B11-cancers-10-00161" ref-type="bibr">11</xref>,<xref rid="B12-cancers-10-00161" ref-type="bibr">12</xref>]. The N terminal region of the Sp1-like transcriptional factor family is variable, therefore, these three transcriptional repressor domains are a critical feature of the KLF10 and KLF11 subfamily. GC-rich sequences of KLF10 play important roles in the regulation of a large number of genes essential for various cellular functions, including cell proliferation, differentiation, and apoptosis [<xref rid="B13-cancers-10-00161" ref-type="bibr">13</xref>]. KLF10 is involved in several different types of gene expression in various cell types and serves as a target gene for many signaling pathways. This gene is known to be induced by estrogen, TGF-&#x003b2;s, bone morphogenetic protein (BMP), nerve growth factor and epidermal growth factor (EGF) depending on cellular and environmental circumstances. One of its potential roles as a transcription factor is that it mimics the anti-proliferative effect of TGF-&#x003b2; and induces apoptosis [<xref rid="B31-cancers-10-00161" ref-type="bibr">31</xref>]. KLF10 and TGF-&#x003b2; induce apoptosis by the formation of ROS (reactive oxygen species) and a loss of the mitochondrial membrane potential [<xref rid="B32-cancers-10-00161" ref-type="bibr">32</xref>]. KLF10 facilitates TGF-&#x003b2; signaling after phosphorylation of the carboxy-terminal serine residue of the internal modulator Smad2/Smad3 protein via TGF-&#x003b2; receptor type I, and interaction with Smad4, the nuclear localized Smad compound, induces expression of KLF10 in order to bind with promoters of Smad2, Smad7, and TGF-&#x003b2;1. KLF10 overexpression increases endogenous TGF-&#x003b2; regulated genes p21 and PAI-1 [<xref rid="B33-cancers-10-00161" ref-type="bibr">33</xref>]. Additionally, KLF10 is regulated by other members of the TGF-&#x003b2; superfamily, such as BMPs, activins and GDNF (glial cell derived neurotrophic factor), which suggests that KLF10 might act in diverse signaling pathways at the transcriptional level.</p></sec><sec id="sec3-cancers-10-00161"><title>3. KLF10 Role in Various Diseases</title><p>KLF10 has the potential for use as a marker for various diseases including diabetes, cardiac hypertrophy, and osteoporosis (<xref rid="cancers-10-00161-t002" ref-type="table">Table 2</xref>).</p><sec id="sec3dot1-cancers-10-00161"><title>3.1. Diabetes</title><p>High blood and tissue concentrations of glucose play a significant role in the development of vascular complications in diabetes mellitus (DM) patients. Loss of KLF10 in liver tissue suppresses glycolytic proteins and encourages gluconeogenic and lipogenic proteins [<xref rid="B43-cancers-10-00161" ref-type="bibr">43</xref>]. KLF10 is a circadian-clock-controlled transcription factor that can suppress lipogenic genes involved in glucose and lipid metabolism in the liver [<xref rid="B44-cancers-10-00161" ref-type="bibr">44</xref>] that also affects hepatic gluconeogenesis, which contributes to T2DM [<xref rid="B36-cancers-10-00161" ref-type="bibr">36</xref>]. However, no apparent pathological defects of pancreatic function were observed under basal conditions in knockout mouse models of KLF10 [<xref rid="B45-cancers-10-00161" ref-type="bibr">45</xref>,<xref rid="B46-cancers-10-00161" ref-type="bibr">46</xref>]. Using real-time PCR analysis, Zitman-Gal et al. found that the expression of KLF10 was also upregulated in a diabetic-like environment, whereas the addition of calcitriol significantly down-regulated KLF10 mRNA expression [<xref rid="B47-cancers-10-00161" ref-type="bibr">47</xref>].</p></sec><sec id="sec3dot2-cancers-10-00161"><title>3.2. Bone Disease</title><p>TGF-&#x003b2;, which plays a major role in osteoblast (OBL) and osteoclast (OCL) functions, is present in large amounts in the skeleton [<xref rid="B48-cancers-10-00161" ref-type="bibr">48</xref>]. KLF10 is one of the key transcriptional regulators in osteogenesis regulated through the TGF-&#x003b2; signaling pathway [<xref rid="B49-cancers-10-00161" ref-type="bibr">49</xref>]. KLF10 knock-out (KO) mice have slow osteoblast production of RANKL (receptor activator of nuclear factor kappa-B ligand) and high levels of osteoprotegerin (OPG), which delays OCL differentiation, leading to a reduced bone turnover and a loss of bone (osteopenia) [<xref rid="B34-cancers-10-00161" ref-type="bibr">34</xref>,<xref rid="B35-cancers-10-00161" ref-type="bibr">35</xref>,<xref rid="B46-cancers-10-00161" ref-type="bibr">46</xref>]. KLF10 also shows osteoclast precursors that differentiate slowly, as well as increased AKT (a serine/threonine-specific protein kinase) and MAPK/ERK (mitogen activated protein kinases/extracellular signal regulated kinases) signaling pathway activation, which is consistent with the roles of these kinases in promoting osteoclast survival. Higher RANKL concentrations can restore this defect, suggesting that KLF10 plays a role in osteogenesis through RANKL signaling [<xref rid="B50-cancers-10-00161" ref-type="bibr">50</xref>].</p></sec><sec id="sec3dot3-cancers-10-00161"><title>3.3. Heart Hypertrophy</title><p>Microarray analysis of heart tissue from the left ventricles of KLF10 KO male, but not female, mice aged 16 months showed a 14-fold increase, increased fibrosis, and increased wall thickness relative to wild-type animals [<xref rid="B37-cancers-10-00161" ref-type="bibr">37</xref>]. Another study reported that KLF10 is downregulated in Angiotensin II (Ang II) induced hypertrophy through repression of expression of the cardiac transcription factor GATA4 and mRNA levels of hypertrophy-related genes atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP) [<xref rid="B51-cancers-10-00161" ref-type="bibr">51</xref>]. TGF-&#x003b2;1 and KLF10 control T regulatory cell differentiation and suppressor function and act as regulators of CD4<sup>+</sup>CD25<sup>&#x02212;</sup> T cell activation. KLF10 in response to TGF-&#x003b2;1 can transactivate both TGF-&#x003b2;1 in CD4+CD25<sup>&#x02212;</sup> T cells and Foxp3 promoters, which is associated with a positive response of KLF10 expressed highly in T regulatory cells [<xref rid="B38-cancers-10-00161" ref-type="bibr">38</xref>]. KLF10 plays a critical role in the regulation of atherosclerotic lesion formation in mice by targeting TGF-&#x003b2;1 to regulate CD4+CD25<sup>&#x02212;</sup> T cells and T regs. KLF10 also complexed with pituitary tumor-transforming gene-1 (Pttg1), which is one of its target genes and plays an important role in cardiac hypertrophy [<xref rid="B37-cancers-10-00161" ref-type="bibr">37</xref>,<xref rid="B52-cancers-10-00161" ref-type="bibr">52</xref>].</p></sec><sec id="sec3dot4-cancers-10-00161"><title>3.4. Other Diseases</title><p>KLF10 are able to physically associate withthe FOXP3 gene to induce transcription and can either positively or negatively regulate FOXP3 through its differential association with p300/CBP-associated factor (PCAF) or the histone deacetylase binding protein Sin3, respectively. Inactivation of immune genes, such as FOXP3, may cause human diseases such as colitis [<xref rid="B53-cancers-10-00161" ref-type="bibr">53</xref>]. In the absence of KLF10, colonic macrophages express lower levels of TGF&#x003b2;RII and reduced Smad2 phosphorylation, resulting in TGF-&#x003b2;1 stimulation that contributes to colitis [<xref rid="B41-cancers-10-00161" ref-type="bibr">41</xref>,<xref rid="B54-cancers-10-00161" ref-type="bibr">54</xref>]. Moreover, transcriptomic analysis of peritoneal cells in a mouse model of sepsis caused by infection with a non-pathogenic strain of <italic>Escherichia coli</italic> revealed that KLF10 was down-regulated at 2 h [<xref rid="B45-cancers-10-00161" ref-type="bibr">45</xref>], while KLF10 induces TGF-&#x003b2;1 expression, which is an anti-inflammatory cytokine and regulates T cell activation [<xref rid="B29-cancers-10-00161" ref-type="bibr">29</xref>]. KLF10 expression was significantly increased in diet-induced nonalcoholic steatohepatitis (NASH) and collagen-producing activated hepatic stellate cells. This up-regulation of KLF10 increased TGF-&#x003b2; signaling genes and suppressed ChREBP expression [<xref rid="B40-cancers-10-00161" ref-type="bibr">40</xref>]. Furthermore, KLF10 plays a role in hyperglycemia [<xref rid="B55-cancers-10-00161" ref-type="bibr">55</xref>], human chronic obstructive pulmonary diseases and liver cirrhosis [<xref rid="B56-cancers-10-00161" ref-type="bibr">56</xref>], tendon repair [<xref rid="B57-cancers-10-00161" ref-type="bibr">57</xref>], and hypoxia [<xref rid="B58-cancers-10-00161" ref-type="bibr">58</xref>]. However, the actual functional role and mechanism of KLF10 in various pathophysiological conditions are still uncertain.</p></sec><sec id="sec3dot5-cancers-10-00161"><title>3.5. Phenotype in KLF10 Deficient Models</title><p>KLF10 deficient animals are widely used to determine its role in different cellular process and diseases. The KO phenotype of KLF10 shows a normal lifespan in mice, but with some defects such as in the microarchitecture and mechanical properties of tendons. The tail tendons of KLF10 KO mice were significantly less stiff than the wild-type controls at 3 months of age, while no difference existed at 1 or 15 months, indicating that there are age-dependent changes in the mechanical properties of the tendon in KLF10 KO mice [<xref rid="B59-cancers-10-00161" ref-type="bibr">59</xref>]. KLF10 display an important role in skeletal development and homeostasis; significantly weaker bones and reduced amounts of cortical and trabecular bone were noticed in the absence of KLF10 [<xref rid="B60-cancers-10-00161" ref-type="bibr">60</xref>]. Additionally, transmission electron microscopy revealed that osteocytes display defects in their morphology, density and surrounding bone matrix [<xref rid="B61-cancers-10-00161" ref-type="bibr">61</xref>]. Moreover, type-I collagen, which is the most abundant collagen found in tendons, was significantly decreased in KLF10 KO tendons [<xref rid="B62-cancers-10-00161" ref-type="bibr">62</xref>].</p><p>KO of KLF10 shows gender-specific osteopenic phenotypes in females characterized by a decrease in the total number of functional/mature OBLs indicating a potential role of KLF10 in mediating estrogen signaling (as well as TGF&#x003b2;) in the skeleton [<xref rid="B63-cancers-10-00161" ref-type="bibr">63</xref>,<xref rid="B64-cancers-10-00161" ref-type="bibr">64</xref>,<xref rid="B65-cancers-10-00161" ref-type="bibr">65</xref>]. Moreover, KLF10 null mice develop age-related hypertrophy [<xref rid="B66-cancers-10-00161" ref-type="bibr">66</xref>]. Loss of KLF10 can delay wound healing and increase Smad 7 in wounds, which causes weakened wound contraction, granulation tissue formation, collagen synthesis, and re-epithelialization [<xref rid="B32-cancers-10-00161" ref-type="bibr">32</xref>,<xref rid="B33-cancers-10-00161" ref-type="bibr">33</xref>]. Its loss has reduced endothelial progenitor cells (EPCs) function and TGF-&#x003b2;1 responsiveness because of impaired blood flow recovery after hindlimb ischemia in systemic KLF10&#x02212;/&#x02212; mice [<xref rid="B67-cancers-10-00161" ref-type="bibr">67</xref>]. KLF10 lacking bone marrow display both basal defects in their ability to migrate and incorporate into the vessel wall and complex paracrine defects in their ability to facilitate endothelial cell (EC) growth and migration [<xref rid="B68-cancers-10-00161" ref-type="bibr">68</xref>].</p></sec></sec><sec id="sec4-cancers-10-00161"><title>4. Role of KLF10 as a Tumor Suppressor in Various Cancers</title><p>KLF10 plays a vital role in many biological processes and diseases, including tumorigenesis (<xref rid="cancers-10-00161-t003" ref-type="table">Table 3</xref>). Many studies have shown that KLF10 acts as a tumor suppressor through TGF-&#x003b2; signaling by playing an important role in inhibition of cell proliferation and induction of apoptosis (<xref ref-type="fig" rid="cancers-10-00161-f002">Figure 2</xref>) [<xref rid="B30-cancers-10-00161" ref-type="bibr">30</xref>,<xref rid="B69-cancers-10-00161" ref-type="bibr">69</xref>]. KLF10 is an effective repressor of cancer cell proliferation, overexpression of KLF10 reduced cell proliferation in many cancer types while in the absence of KLF10 cell proliferation increased, which decreases Smad dependent transcription, and importantly, Smad2/3 in association with a prolonged increase in Smad7 expression. Moreover, KLF10 is a valuable tool to enhance the death of p53 deficient cancer in association with low dose chemotherapy [<xref rid="B70-cancers-10-00161" ref-type="bibr">70</xref>].</p><sec id="sec4dot1-cancers-10-00161"><title>4.1. Liver Cancer</title><p>Loss of TGF-&#x003b2; sensitivity has been assumed to be an event in HCC (hepatocellular carcinoma) development [<xref rid="B84-cancers-10-00161" ref-type="bibr">84</xref>,<xref rid="B85-cancers-10-00161" ref-type="bibr">85</xref>]. Activation of KLF10 gene can promote growth inhibition and apoptosis of TGF-&#x003b2;-susceptible human HCC cells, as well as to inhibit stathmin promoter activity, suggesting stathmin is a direct target of KLF10 [<xref rid="B79-cancers-10-00161" ref-type="bibr">79</xref>]. Furthermore, KLF10 was found to repress glutathione transferase P (GST-P) promoter activity, which is an excellent tumor marker in hepatocarcinogenesis, by binding to GST-P silencer 2 [<xref rid="B86-cancers-10-00161" ref-type="bibr">86</xref>]. Lack of KLF10 blocked cellular proliferation of hepatocytes by encouraging TGF-&#x003b2;/Smad pathway during liver tumorigenesis [<xref rid="B80-cancers-10-00161" ref-type="bibr">80</xref>]. Koczulla et al. reported that KLF10 is highly expressed in liver cirrhosis [<xref rid="B56-cancers-10-00161" ref-type="bibr">56</xref>]; however, there is inadequate information regarding KLF10, and the actual functions of KLF10 in liver tumorigenesis are controversial.</p></sec><sec id="sec4dot2-cancers-10-00161"><title>4.2. Pancreatic Cancer</title><p>KLF10 expression is inversely associated with pancreatic cancer and therefore, KLF10 can be used as a predictive indicator for pancreatic cancer stages [<xref rid="B87-cancers-10-00161" ref-type="bibr">87</xref>]. KLF10 is expressed in both acinar and ductular epithelial cell populations and plays a significant role in the pancreatic &#x003b2;-cells. Loss of this gene increases p21<sup>Cip1</sup> in islet cells, which are associated with impaired glucose tolerance and impaired insulin secretion [<xref rid="B30-cancers-10-00161" ref-type="bibr">30</xref>,<xref rid="B88-cancers-10-00161" ref-type="bibr">88</xref>]. KLF10 overexpression in the TGF-&#x003b2; sensitive pancreatic human cell line is sufficient to induce apoptosis [<xref rid="B89-cancers-10-00161" ref-type="bibr">89</xref>]. Furthermore, its overexpression-induced cell cycle arrest at the G1- to S-phase transition to inhibit human pancreatic cancer SW1990 cell proliferation [<xref rid="B77-cancers-10-00161" ref-type="bibr">77</xref>]. KLF10 is located on chromosome 8q22, where mutations are quite frequent in pancreatic cancers [<xref rid="B90-cancers-10-00161" ref-type="bibr">90</xref>]; however, mutational screening of a panel of the twenty-two human pancreatic cell lines showed no alteration in KLF10 expression [<xref rid="B78-cancers-10-00161" ref-type="bibr">78</xref>].</p></sec><sec id="sec4dot3-cancers-10-00161"><title>4.3. Lung Cancer</title><p>KLF10 occupied GC-rich sequences in the promoter region of EMT (epithelial mesenchymal transition) promoting transcription factor SLUG/SNAI2 (snail family zinc finger 2) and acted as the main factor of the TGF-&#x003b2;1 related EMT program [<xref rid="B91-cancers-10-00161" ref-type="bibr">91</xref>]. Mishra et al. reported that KLF10 suppresses TGF-&#x003b2; induced EMT by binding and repressing the SNAI2 promoter as a direct KLF10 target gene through HDAC1 in lung and pancreatic cancer models [<xref rid="B82-cancers-10-00161" ref-type="bibr">82</xref>]. Furthermore, in vitro and in vivo studies showed decreased tumor growth and increased chemo-sensitivity to gemcitabine through G0/G1 cell cycle arrest after Cul4A (cullin 4A) knockdown, which is an important regulator of proliferation and cell cycle progression in lung cancer. In addition, Cul4A knockdown increases the expression of KLF10, cyclin-dependent kinase inhibitor p21/WAF1, and TGF-&#x003b2;1, which play a role as tumor suppressors [<xref rid="B92-cancers-10-00161" ref-type="bibr">92</xref>].</p></sec><sec id="sec4dot4-cancers-10-00161"><title>4.4. Breast Cancer</title><p>KLF10 and its target genes play important roles in breast cancer. KLF10 has been indicated as a marker for breast cancer, and different stages of breast tumor tissues from different populations show decreased mRNA levels of KLF10, Smad2, and BRAD1 (breast cancer 1 associated RING domain 1), while Smad7 is inversely correlated with KLF10 [<xref rid="B73-cancers-10-00161" ref-type="bibr">73</xref>]. KLF10 is an anti-metastasis gene that significantly prevents breast cancer cell invasion, suppresses mammary tumorigenesis and decreases lung metastasis by inhibition of EGFR (epidermal growth factor receptor) gene transcription through the EGFR signaling pathway [<xref rid="B93-cancers-10-00161" ref-type="bibr">93</xref>]. Furthermore, Hsu et al. reported a significant E2/Klf10/BI-1/cytoplasmic calcium pathway in which E2 (estrogen) induces apoptosis through increased expression of KLF10, which decreases BI-1 (Bax inhibitor-1) transcription and finally increases the concentration of Ca<sup>2+</sup>(cytoplasmic calcium) [<xref rid="B94-cancers-10-00161" ref-type="bibr">94</xref>]. The above studies strongly support KLF10 as a tumor suppressor protein that plays an inhibitory role in the proliferation of breast cancer.</p></sec><sec id="sec4dot5-cancers-10-00161"><title>4.5. Colon Cancer</title><p>KLF10 is believed to be a tumor suppressor gene in many cancers (<xref rid="cancers-10-00161-t002" ref-type="table">Table 2</xref>), including human colorectal cancer. Additionally, it is one of the members of the signal transduction of the peroxisome proliferator-activated receptor gamma (PPAR&#x003b3;) pathway in human colorectal cancer cells. Human colorectal cancer cells express abundant PPAR&#x003b3;, but its inhibitory function is very low, signifying a defect in the PPAR&#x003b3; pathway [<xref rid="B95-cancers-10-00161" ref-type="bibr">95</xref>]. Treatment of colon cancer cells with 15-hydroxy-eicosatetraenoic acid (15S-HETE), an endogenous ligand for PPAR&#x003b3;, arrests the growth of colon cancer cells via a PPAR&#x003b3; dependent pathway involving increased expression of KLF10 and decreased Bcl-2 (B cell lymphoma 2) expressions [<xref rid="B72-cancers-10-00161" ref-type="bibr">72</xref>].</p></sec><sec id="sec4dot6-cancers-10-00161"><title>4.6. Human Prostate Cancer</title><p>Instigation of the TGF-&#x003b2;1 pathway triggers doxazosin-based apoptotic effect in prostate cancer cells. Doxazosin is an &#x003b1;1-selective alpha blocker used to treat high blood pressure and urinary retention related to benign prostatic hyperplasia (BPH). In vitro analysis has shown that treatment of PC-3 prostate cancer cells with doxazosin resulted in a marked induction in KLF10 and Smad4 mRNA levels, as well as a transient decrease in Smad7 mRNA expression. Smad4 is an important regulator of TGF-&#x003b2;1 signaling and apoptosis in a variety of cell lines [<xref rid="B71-cancers-10-00161" ref-type="bibr">71</xref>,<xref rid="B96-cancers-10-00161" ref-type="bibr">96</xref>,<xref rid="B97-cancers-10-00161" ref-type="bibr">97</xref>].</p></sec><sec id="sec4dot7-cancers-10-00161"><title>4.7. Metastatic Brain Tumors</title><p>Metastasis is a procedure in which cancerous cells spread from the initial or primary tumor, enter the bloodstream or lymphatic system, and spreads to different or secondary sites within the body in numerous malignant neoplasms, including breast, lung, and ovarian cancer. Gene expression profiling using a 17k-expression array of metastatic brain tumors from primary lung adenocarcinoma revealed that KLF10, which is a gene involved in apoptosis, was expressed at insufficient or abnormally low levels in metastatic brain tumors, suggesting KLF10 acts as a tumor-repressor gene [<xref rid="B75-cancers-10-00161" ref-type="bibr">75</xref>].</p></sec><sec id="sec4dot8-cancers-10-00161"><title>4.8. Renal Cancer</title><p>KLF10 facilitates up-regulation of TGF-&#x003b2;1 in VHL (von Hippel-lindau) deficient tumors. In a Luc-reporter assay, a potential KLF10 binding site was identified in the TGF-&#x003b2;1 promoter upstream from the transcription initiation site, which is also recognized as a Sp1-binding site. KLF10 was suppressed in the renal cancer cell line by wild-VHL and not from mutant VHL cells, suggesting that it may also serve as a VHL target. Stimulation of the TGF-&#x003b2;1 promoter by KLF10 in HAEo(&#x02212;) and 293 cells suggests that KLF10 is a VHL target that regulates the TGF-&#x003b2;1 promoter in renal cell carcinoma [<xref rid="B76-cancers-10-00161" ref-type="bibr">76</xref>].</p></sec><sec id="sec4dot9-cancers-10-00161"><title>4.9. Other Cancers</title><p>Smad signaling is present in certain different human lymphoma cells. However, in lymphoma cancer, the contribution of Smads to TGF-&#x003b2; induced apoptosis is supported by the increased expression of KLF10, which is a Smad-responsive gene [<xref rid="B74-cancers-10-00161" ref-type="bibr">74</xref>,<xref rid="B98-cancers-10-00161" ref-type="bibr">98</xref>]. KLF10 has been recognized as a direct downstream target of miR-410 in multiple myelomas (MM) cells and facilitates the effects of miR-410 in MM, resulting in PTEN (phosphatase and tension homolog)/AKT activation [<xref rid="B42-cancers-10-00161" ref-type="bibr">42</xref>,<xref rid="B99-cancers-10-00161" ref-type="bibr">99</xref>]. KLF10 is a circadian transcriptional regulator that links the molecular clock to energy metabolism [<xref rid="B44-cancers-10-00161" ref-type="bibr">44</xref>]. In ovarian cancer, transcription factor KLF10 activated by circadian rhythm gene expression serves as a risk factor for epithelial ovarian cancer, histopathologic subtype, and invasiveness [<xref rid="B81-cancers-10-00161" ref-type="bibr">81</xref>]. The zinc finger transcription factor KLF10 regulates myeloid-specific activation of the leukocyte integrin CD11d promoter [<xref rid="B100-cancers-10-00161" ref-type="bibr">100</xref>]. Co-transfection and electrophoretic mobility shift have revealed that KLF10 competes with these SP proteins for binding to overlapping sites in the CD11d promoter. Stimulation of CD11d expression resulting in differentiation of myeloid cells is mediated through increased binding of KLF10 to the CD11d promoter [<xref rid="B101-cancers-10-00161" ref-type="bibr">101</xref>].</p></sec></sec><sec id="sec5-cancers-10-00161"><title>5. Concluding Remarks</title><p>KLF10 plays an active role in the etiology and development of many mammalian diseases and appears to have unique tissue-specific roles that were identified primarily using in vivo experiments, including gene knockout models. KLF10 is believed to play a crucial role in inhibition of cancer cell proliferation and promotion of apoptosis, which strongly indicate its role as a tumor suppressor. However, there is limited information regarding the mechanism of its role in cancer. The majority of the KLF10 role and gene targeting is mediated through TGF-&#x003b2; signaling. Taken together, the results of the studies discussed indicate that KLF10 can have profound effects as a tumor suppressor in many cancers via TGF-&#x003b2;/Smad dependent and independent pathways. Further understanding of its function and target genes are needed to provide additional insights into the mechanisms of action of KLF10 to understand its role in diseases, including cancer.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported by an Inha University Research Grant (INHA-54680).</p></ack><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-cancers-10-00161"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>J.</given-names></name><name><surname>Crossley</surname><given-names>M.</given-names></name></person-group><article-title>Mammalian Kruppel-like transcription factors: More than just a pretty finger</article-title><source>Trends Biochem. Sci.</source><year>1999</year><volume>24</volume><fpage>236</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1016/S0968-0004(99)01406-1</pub-id><pub-id pub-id-type="pmid">10366853</pub-id></element-citation></ref><ref id="B2-cancers-10-00161"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dynan</surname><given-names>W.S.</given-names></name><name><surname>Tjian</surname><given-names>R.</given-names></name></person-group><article-title>The promoter-specific transcription factor sp1 binds to upstream sequences in the SV40 early promoter</article-title><source>Cell</source><year>1983</year><volume>35</volume><fpage>79</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(83)90210-6</pub-id><pub-id pub-id-type="pmid">6313230</pub-id></element-citation></ref><ref id="B3-cancers-10-00161"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pei</surname><given-names>J.</given-names></name><name><surname>Grishin</surname><given-names>N.V.</given-names></name></person-group><article-title>A new family of predicted Kruppel-like factor genes and pseudogenes in placental mammals</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e81109</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0081109</pub-id><pub-id pub-id-type="pmid">24244731</pub-id></element-citation></ref><ref id="B4-cancers-10-00161"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaczynski</surname><given-names>J.</given-names></name><name><surname>Cook</surname><given-names>T.</given-names></name><name><surname>Urrutia</surname><given-names>R.</given-names></name></person-group><article-title>Sp1- and Kruppel-like transcription factors</article-title><source>Genome Biol.</source><year>2003</year><volume>4</volume><fpage>206</fpage><pub-id pub-id-type="doi">10.1186/gb-2003-4-2-206</pub-id><pub-id pub-id-type="pmid">12620113</pub-id></element-citation></ref><ref id="B5-cancers-10-00161"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearson</surname><given-names>R.</given-names></name><name><surname>Fleetwood</surname><given-names>J.</given-names></name><name><surname>Eaton</surname><given-names>S.</given-names></name><name><surname>Crossley</surname><given-names>M.</given-names></name><name><surname>Bao</surname><given-names>S.</given-names></name></person-group><article-title>Kruppel-like transcription factors: A functional family</article-title><source>Int. J. Biochem. Cell Biol.</source><year>2008</year><volume>40</volume><fpage>1996</fpage><lpage>2001</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2007.07.018</pub-id><pub-id pub-id-type="pmid">17904406</pub-id></element-citation></ref><ref id="B6-cancers-10-00161"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>I.J.</given-names></name><name><surname>Bieker</surname><given-names>J.J.</given-names></name></person-group><article-title>A novel, erythroid cell-specific murine transcription factor that binds to the CACCC element and is related to the Kruppel family of nuclear proteins</article-title><source>Mol. Cell. Biol.</source><year>1993</year><volume>13</volume><fpage>2776</fpage><lpage>2786</lpage><pub-id pub-id-type="doi">10.1128/MCB.13.5.2776</pub-id><pub-id pub-id-type="pmid">7682653</pub-id></element-citation></ref><ref id="B7-cancers-10-00161"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>S.M.</given-names></name><name><surname>Houzelstein</surname><given-names>D.</given-names></name><name><surname>Dunwoodie</surname><given-names>S.L.</given-names></name><name><surname>Beddington</surname><given-names>R.S.</given-names></name></person-group><article-title>Sp5, a new member of the Sp1 family, is dynamically expressed during development and genetically interacts with Brachyury</article-title><source>Dev. Biol.</source><year>2000</year><volume>227</volume><fpage>358</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1006/dbio.2000.9878</pub-id><pub-id pub-id-type="pmid">11071760</pub-id></element-citation></ref><ref id="B8-cancers-10-00161"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramaniam</surname><given-names>M.</given-names></name><name><surname>Harris</surname><given-names>S.A.</given-names></name><name><surname>Oursler</surname><given-names>M.J.</given-names></name><name><surname>Rasmussen</surname><given-names>K.</given-names></name><name><surname>Riggs</surname><given-names>B.L.</given-names></name><name><surname>Spelsberg</surname><given-names>T.C.</given-names></name></person-group><article-title>Identification of a novel TGF-beta-regulated gene encoding a putative zinc finger protein in human osteoblasts</article-title><source>Nucleic Acids Res.</source><year>1995</year><volume>23</volume><fpage>4907</fpage><lpage>4912</lpage><pub-id pub-id-type="doi">10.1093/nar/23.23.4907</pub-id><pub-id pub-id-type="pmid">8532536</pub-id></element-citation></ref><ref id="B9-cancers-10-00161"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>T.</given-names></name><name><surname>Gebelein</surname><given-names>B.</given-names></name><name><surname>Mesa</surname><given-names>K.</given-names></name><name><surname>Mladek</surname><given-names>A.</given-names></name><name><surname>Urrutia</surname><given-names>R.</given-names></name></person-group><article-title>Molecular cloning and characterization of TIEG2 reveals a new subfamily of transforming growth factor-beta-inducible sp1-like zinc finger-encoding genes involved in the regulation of cell growth</article-title><source>J. Biol. Chem.</source><year>1998</year><volume>273</volume><fpage>25929</fpage><lpage>25936</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.40.25929</pub-id><pub-id pub-id-type="pmid">9748269</pub-id></element-citation></ref><ref id="B10-cancers-10-00161"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>K.P.</given-names></name><name><surname>Kern</surname><given-names>C.B.</given-names></name><name><surname>Crable</surname><given-names>S.C.</given-names></name><name><surname>Lingrel</surname><given-names>J.B.</given-names></name></person-group><article-title>Isolation of a gene encoding a functional zinc finger protein homologous to erythroid Kruppel-like factor: Identification of a new multigene family</article-title><source>Mol. Cell. Biol.</source><year>1995</year><volume>15</volume><fpage>5957</fpage><lpage>5965</lpage><pub-id pub-id-type="doi">10.1128/MCB.15.11.5957</pub-id><pub-id pub-id-type="pmid">7565748</pub-id></element-citation></ref><ref id="B11-cancers-10-00161"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crossley</surname><given-names>M.</given-names></name><name><surname>Whitelaw</surname><given-names>E.</given-names></name><name><surname>Perkins</surname><given-names>A.</given-names></name><name><surname>Williams</surname><given-names>G.</given-names></name><name><surname>Fujiwara</surname><given-names>Y.</given-names></name><name><surname>Orkin</surname><given-names>S.H.</given-names></name></person-group><article-title>Isolation and characterization of the CDNA encoding BKLF/TEF-2, a major CACCC-box-binding protein in erythroid cells and selected other cells</article-title><source>Mol. Cell. Biol.</source><year>1996</year><volume>16</volume><fpage>1695</fpage><lpage>1705</lpage><pub-id pub-id-type="doi">10.1128/MCB.16.4.1695</pub-id><pub-id pub-id-type="pmid">8657145</pub-id></element-citation></ref><ref id="B12-cancers-10-00161"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shields</surname><given-names>J.M.</given-names></name><name><surname>Christy</surname><given-names>R.J.</given-names></name><name><surname>Yang</surname><given-names>V.W.</given-names></name></person-group><article-title>Identification and characterization of a gene encoding a gut-enriched Kruppel-like factor expressed during growth arrest</article-title><source>J. Biol. Chem.</source><year>1996</year><volume>271</volume><fpage>20009</fpage><lpage>20017</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.33.20009</pub-id><pub-id pub-id-type="pmid">8702718</pub-id></element-citation></ref><ref id="B13-cancers-10-00161"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imataka</surname><given-names>H.</given-names></name><name><surname>Sogawa</surname><given-names>K.</given-names></name><name><surname>Yasumoto</surname><given-names>K.</given-names></name><name><surname>Kikuchi</surname><given-names>Y.</given-names></name><name><surname>Sasano</surname><given-names>K.</given-names></name><name><surname>Kobayashi</surname><given-names>A.</given-names></name><name><surname>Hayami</surname><given-names>M.</given-names></name><name><surname>Fujii-Kuriyama</surname><given-names>Y.</given-names></name></person-group><article-title>Two regulatory proteins that bind to the basic transcription element (BTE), a GC box sequence in the promoter region of the rat P-4501A1 gene</article-title><source>EMBO J.</source><year>1992</year><volume>11</volume><fpage>3663</fpage><lpage>3671</lpage><pub-id pub-id-type="pmid">1356762</pub-id></element-citation></ref><ref id="B14-cancers-10-00161"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conkright</surname><given-names>M.D.</given-names></name><name><surname>Wani</surname><given-names>M.A.</given-names></name><name><surname>Anderson</surname><given-names>K.P.</given-names></name><name><surname>Lingrel</surname><given-names>J.B.</given-names></name></person-group><article-title>A gene encoding an intestinal-enriched member of the Kruppel-like factor family expressed in intestinal epithelial cells</article-title><source>Nucleic Acids Res.</source><year>1999</year><volume>27</volume><fpage>1263</fpage><lpage>1270</lpage><pub-id pub-id-type="doi">10.1093/nar/27.5.1263</pub-id><pub-id pub-id-type="pmid">9973612</pub-id></element-citation></ref><ref id="B15-cancers-10-00161"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suske</surname><given-names>G.</given-names></name><name><surname>Bruford</surname><given-names>E.</given-names></name><name><surname>Philipsen</surname><given-names>S.</given-names></name></person-group><article-title>Mammalian SP/KLF transcription factors: Bring in the family</article-title><source>Genomics</source><year>2005</year><volume>85</volume><fpage>551</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1016/j.ygeno.2005.01.005</pub-id><pub-id pub-id-type="pmid">15820306</pub-id></element-citation></ref><ref id="B16-cancers-10-00161"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>W.</given-names></name><name><surname>Burns</surname><given-names>K.H.</given-names></name><name><surname>Ma</surname><given-names>L.</given-names></name><name><surname>Matzuk</surname><given-names>M.M.</given-names></name></person-group><article-title>Identification of Zfp393, a germ cell-specific gene encoding a novel zinc finger protein</article-title><source>Mech. Dev.</source><year>2002</year><volume>118</volume><fpage>233</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/S0925-4773(02)00258-7</pub-id><pub-id pub-id-type="pmid">12351194</pub-id></element-citation></ref><ref id="B17-cancers-10-00161"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McConnell</surname><given-names>B.B.</given-names></name><name><surname>Yang</surname><given-names>V.W.</given-names></name></person-group><article-title>Mammalian Kruppel-like factors in health and diseases</article-title><source>Physiol. Rev.</source><year>2010</year><volume>90</volume><fpage>1337</fpage><lpage>1381</lpage><pub-id pub-id-type="doi">10.1152/physrev.00058.2009</pub-id><pub-id pub-id-type="pmid">20959618</pub-id></element-citation></ref><ref id="B18-cancers-10-00161"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>J.A.</given-names></name><name><surname>McAlpine</surname><given-names>P.J.</given-names></name><name><surname>Antonarakis</surname><given-names>S.</given-names></name><name><surname>Cann</surname><given-names>H.</given-names></name><name><surname>Eppig</surname><given-names>J.T.</given-names></name><name><surname>Frazer</surname><given-names>K.</given-names></name><name><surname>Frezal</surname><given-names>J.</given-names></name><name><surname>Lancet</surname><given-names>D.</given-names></name><name><surname>Nahmias</surname><given-names>J.</given-names></name><name><surname>Pearson</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Guidelines for human gene nomenclature (1997). Hugo nomenclature committee</article-title><source>Genomics</source><year>1997</year><volume>45</volume><fpage>468</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1006/geno.1997.4979</pub-id><pub-id pub-id-type="pmid">9344684</pub-id></element-citation></ref><ref id="B19-cancers-10-00161"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>A.R.</given-names></name><name><surname>Black</surname><given-names>J.D.</given-names></name><name><surname>Azizkhan-Clifford</surname><given-names>J.</given-names></name></person-group><article-title>Sp1 and Kruppel-like factor family of transcription factors in cell growth regulation and cancer</article-title><source>J. Cell. Physiol.</source><year>2001</year><volume>188</volume><fpage>143</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1002/jcp.1111</pub-id><pub-id pub-id-type="pmid">11424081</pub-id></element-citation></ref><ref id="B20-cancers-10-00161"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Presnell</surname><given-names>J.S.</given-names></name><name><surname>Schnitzler</surname><given-names>C.E.</given-names></name><name><surname>Browne</surname><given-names>W.E.</given-names></name></person-group><article-title>KLF/SP transcription factor family evolution: Expansion, diversification, and innovation in eukaryotes</article-title><source>Genome Biol. Evol.</source><year>2015</year><volume>7</volume><fpage>2289</fpage><lpage>2309</lpage><pub-id pub-id-type="doi">10.1093/gbe/evv141</pub-id><pub-id pub-id-type="pmid">26232396</pub-id></element-citation></ref><ref id="B21-cancers-10-00161"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollak</surname><given-names>N.M.</given-names></name><name><surname>Hoffman</surname><given-names>M.</given-names></name><name><surname>Goldberg</surname><given-names>I.J.</given-names></name><name><surname>Drosatos</surname><given-names>K.</given-names></name></person-group><article-title>Kr&#x000fc;ppel-like factors: Crippling and uncrippling metabolic pathways</article-title><source>JACC Basic Transl. Sci.</source><year>2018</year><volume>3</volume><fpage>132</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/j.jacbts.2017.09.001</pub-id><pub-id pub-id-type="pmid">29876529</pub-id></element-citation></ref><ref id="B22-cancers-10-00161"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>T.</given-names></name><name><surname>Gebelein</surname><given-names>B.</given-names></name><name><surname>Urrutia</surname><given-names>R.</given-names></name></person-group><article-title>Sp1 and its likes: Biochemical and functional predictions for a growing family of zinc finger transcription factors</article-title><source>Ann. N. Y. Acad. Sci.</source><year>1999</year><volume>880</volume><fpage>94</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.1999.tb09513.x</pub-id><pub-id pub-id-type="pmid">10415854</pub-id></element-citation></ref><ref id="B23-cancers-10-00161"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname><given-names>D.T.</given-names></name><name><surname>Pevsner</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>V.W.</given-names></name></person-group><article-title>The biology of the mammalian Kruppel-like family of transcription factors</article-title><source>Int. J. Biochem. Cell Biol.</source><year>2000</year><volume>32</volume><fpage>1103</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.1016/S1357-2725(00)00059-5</pub-id><pub-id pub-id-type="pmid">11137451</pub-id></element-citation></ref><ref id="B24-cancers-10-00161"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Philipsen</surname><given-names>S.</given-names></name><name><surname>Suske</surname><given-names>G.</given-names></name></person-group><article-title>A tale of three fingers: The family of mammalian Sp/XKLF transcription factors</article-title><source>Nucleic Acids Res.</source><year>1999</year><volume>27</volume><fpage>2991</fpage><lpage>3000</lpage><pub-id pub-id-type="doi">10.1093/nar/27.15.2991</pub-id><pub-id pub-id-type="pmid">10454592</pub-id></element-citation></ref><ref id="B25-cancers-10-00161"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>J.</given-names></name><name><surname>Crossley</surname><given-names>M.</given-names></name></person-group><article-title>Basic Kruppel-like factor functions within a network of interacting haematopoietic transcription factors</article-title><source>Int. J. Biochem. Cell Biol.</source><year>1999</year><volume>31</volume><fpage>1169</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1016/S1357-2725(99)00067-9</pub-id><pub-id pub-id-type="pmid">10582345</pub-id></element-citation></ref><ref id="B26-cancers-10-00161"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmierer</surname><given-names>B.</given-names></name><name><surname>Hill</surname><given-names>C.S.</given-names></name></person-group><article-title>TGFbeta-SMAD signal transduction: Molecular specificity and functional flexibility</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2007</year><volume>8</volume><fpage>970</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1038/nrm2297</pub-id><pub-id pub-id-type="pmid">18000526</pub-id></element-citation></ref><ref id="B27-cancers-10-00161"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrighton</surname><given-names>K.H.</given-names></name><name><surname>Lin</surname><given-names>X.</given-names></name><name><surname>Feng</surname><given-names>X.H.</given-names></name></person-group><article-title>Phospho-control of TGF-beta superfamily signaling</article-title><source>Cell Res.</source><year>2009</year><volume>19</volume><fpage>8</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1038/cr.2008.327</pub-id><pub-id pub-id-type="pmid">19114991</pub-id></element-citation></ref><ref id="B28-cancers-10-00161"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goumans</surname><given-names>M.J.</given-names></name><name><surname>Valdimarsdottir</surname><given-names>G.</given-names></name><name><surname>Itoh</surname><given-names>S.</given-names></name><name><surname>Lebrin</surname><given-names>F.</given-names></name><name><surname>Larsson</surname><given-names>J.</given-names></name><name><surname>Mummery</surname><given-names>C.</given-names></name><name><surname>Karlsson</surname><given-names>S.</given-names></name><name><surname>ten Dijke</surname><given-names>P.</given-names></name></person-group><article-title>Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling</article-title><source>Mol. Cell</source><year>2003</year><volume>12</volume><fpage>817</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(03)00386-1</pub-id><pub-id pub-id-type="pmid">14580334</pub-id></element-citation></ref><ref id="B29-cancers-10-00161"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiffer</surname><given-names>M.</given-names></name><name><surname>Von Gersdorff</surname><given-names>G.</given-names></name><name><surname>Bitzer</surname><given-names>M.</given-names></name><name><surname>Susztak</surname><given-names>K.</given-names></name><name><surname>B&#x000f6;ttinger</surname><given-names>E.P.</given-names></name></person-group><article-title>SMAD proteins and transforming growth factor-&#x003b2; signaling</article-title><source>Kidney Int.</source><year>2000</year><volume>58</volume><fpage>S45</fpage><lpage>S52</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.2000.07708.x</pub-id></element-citation></ref><ref id="B30-cancers-10-00161"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tachibana</surname><given-names>I.</given-names></name><name><surname>Imoto</surname><given-names>M.</given-names></name><name><surname>Adjei</surname><given-names>P.N.</given-names></name><name><surname>Gores</surname><given-names>G.J.</given-names></name><name><surname>Subramaniam</surname><given-names>M.</given-names></name><name><surname>Spelsberg</surname><given-names>T.C.</given-names></name><name><surname>Urrutia</surname><given-names>R.</given-names></name></person-group><article-title>Overexpression of the TGFbeta-regulated zinc finger encoding gene, TIEG, induces apoptosis in pancreatic epithelial cells</article-title><source>J. Clin. Investig.</source><year>1997</year><volume>99</volume><fpage>2365</fpage><lpage>2374</lpage><pub-id pub-id-type="doi">10.1172/JCI119418</pub-id><pub-id pub-id-type="pmid">9153278</pub-id></element-citation></ref><ref id="B31-cancers-10-00161"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>W.</given-names></name><name><surname>Di</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Cheng</surname><given-names>T.</given-names></name><name><surname>Yao</surname><given-names>M.</given-names></name><name><surname>Shao</surname><given-names>Z.</given-names></name></person-group><article-title>TIEG1 induces apoptosis through mitochondrial apoptotic pathway and promotes apoptosis induced by homoharringtonine and velcade</article-title><source>FEBS Lett.</source><year>2007</year><volume>581</volume><fpage>3826</fpage><lpage>3832</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2007.07.008</pub-id><pub-id pub-id-type="pmid">17659279</pub-id></element-citation></ref><ref id="B32-cancers-10-00161"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>A.</given-names></name><name><surname>Bronk</surname><given-names>S.F.</given-names></name><name><surname>Roberts</surname><given-names>P.J.</given-names></name><name><surname>Urrutia</surname><given-names>R.</given-names></name><name><surname>Gores</surname><given-names>G.J.</given-names></name></person-group><article-title>The transforming growth factor beta(1)-inducible transcription factor tieg1, mediates apoptosis through oxidative stress</article-title><source>Hepatology</source><year>1999</year><volume>30</volume><fpage>1490</fpage><lpage>1497</lpage><pub-id pub-id-type="doi">10.1002/hep.510300620</pub-id><pub-id pub-id-type="pmid">10573529</pub-id></element-citation></ref><ref id="B33-cancers-10-00161"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnsen</surname><given-names>S.A.</given-names></name><name><surname>Subramaniam</surname><given-names>M.</given-names></name><name><surname>Janknecht</surname><given-names>R.</given-names></name><name><surname>Spelsberg</surname><given-names>T.C.</given-names></name></person-group><article-title>TGFbeta inducible early gene enhances TGFbeta/SMAD-dependent transcriptional responses</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><fpage>5783</fpage><lpage>5790</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1205681</pub-id><pub-id pub-id-type="pmid">12173049</pub-id></element-citation></ref><ref id="B34-cancers-10-00161"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramaniam</surname><given-names>M.</given-names></name><name><surname>Hawse</surname><given-names>J.R.</given-names></name><name><surname>Johnsen</surname><given-names>S.A.</given-names></name><name><surname>Spelsberg</surname><given-names>T.C.</given-names></name></person-group><article-title>Role of TIEG1 in biological processes and disease states</article-title><source>J. Cell. Biochem.</source><year>2007</year><volume>102</volume><fpage>539</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1002/jcb.21492</pub-id><pub-id pub-id-type="pmid">17729309</pub-id></element-citation></ref><ref id="B35-cancers-10-00161"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawse</surname><given-names>J.R.</given-names></name><name><surname>Cicek</surname><given-names>M.</given-names></name><name><surname>Grygo</surname><given-names>S.B.</given-names></name><name><surname>Bruinsma</surname><given-names>E.S.</given-names></name><name><surname>Rajamannan</surname><given-names>N.M.</given-names></name><name><surname>van Wijnen</surname><given-names>A.J.</given-names></name><name><surname>Lian</surname><given-names>J.B.</given-names></name><name><surname>Stein</surname><given-names>G.S.</given-names></name><name><surname>Oursler</surname><given-names>M.J.</given-names></name><name><surname>Subramaniam</surname><given-names>M.</given-names></name><etal/></person-group><article-title>TIEG1/KLF10 modulates Runx2 expression and activity in osteoblasts</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e19429</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0019429</pub-id><pub-id pub-id-type="pmid">21559363</pub-id></element-citation></ref><ref id="B36-cancers-10-00161"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutierrez-Aguilar</surname><given-names>R.</given-names></name><name><surname>Benmezroua</surname><given-names>Y.</given-names></name><name><surname>Balkau</surname><given-names>B.</given-names></name><name><surname>Marre</surname><given-names>M.</given-names></name><name><surname>Helbecque</surname><given-names>N.</given-names></name><name><surname>Charpentier</surname><given-names>G.</given-names></name><name><surname>Polychronakos</surname><given-names>C.</given-names></name><name><surname>Sladek</surname><given-names>R.</given-names></name><name><surname>Froguel</surname><given-names>P.</given-names></name><name><surname>Neve</surname><given-names>B.</given-names></name></person-group><article-title>Minor contribution of SMAD7 and KLF10 variants to genetic susceptibility of type 2 diabetes</article-title><source>Diabetes Metab.</source><year>2007</year><volume>33</volume><fpage>372</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1016/j.diabet.2007.06.002</pub-id><pub-id pub-id-type="pmid">17931948</pub-id></element-citation></ref><ref id="B37-cancers-10-00161"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajamannan</surname><given-names>N.M.</given-names></name><name><surname>Subramaniam</surname><given-names>M.</given-names></name><name><surname>Abraham</surname><given-names>T.P.</given-names></name><name><surname>Vasile</surname><given-names>V.C.</given-names></name><name><surname>Ackerman</surname><given-names>M.J.</given-names></name><name><surname>Monroe</surname><given-names>D.G.</given-names></name><name><surname>Chew</surname><given-names>T.L.</given-names></name><name><surname>Spelsberg</surname><given-names>T.C.</given-names></name></person-group><article-title>TGFbeta inducible early gene-1 (TIEG1) and cardiac hypertrophy: Discovery and characterization of a novel signaling pathway</article-title><source>J. Cell. Biochem.</source><year>2007</year><volume>100</volume><fpage>315</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1002/jcb.21049</pub-id><pub-id pub-id-type="pmid">16888812</pub-id></element-citation></ref><ref id="B38-cancers-10-00161"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Z.</given-names></name><name><surname>Wara</surname><given-names>A.K.</given-names></name><name><surname>Icli</surname><given-names>B.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Packard</surname><given-names>R.R.</given-names></name><name><surname>Esen</surname><given-names>F.</given-names></name><name><surname>Stapleton</surname><given-names>C.J.</given-names></name><name><surname>Subramaniam</surname><given-names>M.</given-names></name><name><surname>Kretschmer</surname><given-names>K.</given-names></name><name><surname>Apostolou</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Kruppel-like factor KLF10 targets transforming growth factor-beta1 to regulate CD4(+)CD25(&#x02212;) T cells and T regulatory cells</article-title><source>J. Biol. Chem.</source><year>2009</year><volume>284</volume><fpage>24914</fpage><lpage>24924</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.000059</pub-id><pub-id pub-id-type="pmid">19602726</pub-id></element-citation></ref><ref id="B39-cancers-10-00161"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hori</surname><given-names>K.</given-names></name><name><surname>Ding</surname><given-names>J.</given-names></name><name><surname>Marcoux</surname><given-names>Y.</given-names></name><name><surname>Iwashina</surname><given-names>T.</given-names></name><name><surname>Sakurai</surname><given-names>H.</given-names></name><name><surname>Tredget</surname><given-names>E.E.</given-names></name></person-group><article-title>Impaired cutaneous wound healing in transforming growth factor-beta inducible early gene1 knockout mice</article-title><source>Wound Repair Regen.</source><year>2012</year><volume>20</volume><fpage>166</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1111/j.1524-475X.2012.00773.x</pub-id><pub-id pub-id-type="pmid">22380689</pub-id></element-citation></ref><ref id="B40-cancers-10-00161"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.K.</given-names></name><name><surname>Lee</surname><given-names>K.S.</given-names></name><name><surname>Chang</surname><given-names>H.Y.</given-names></name><name><surname>Lee</surname><given-names>W.K.</given-names></name><name><surname>Lee</surname><given-names>J.I.</given-names></name></person-group><article-title>Progression of diet induced nonalcoholic steatohepatitis is accompanied by increased expression of Kruppel-like-factor 10 in mice</article-title><source>J. Transl. Med.</source><year>2014</year><volume>12</volume><fpage>186</fpage><pub-id pub-id-type="doi">10.1186/1479-5876-12-186</pub-id><pub-id pub-id-type="pmid">24986741</pub-id></element-citation></ref><ref id="B41-cancers-10-00161"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papadakis</surname><given-names>K.A.</given-names></name><name><surname>Krempski</surname><given-names>J.</given-names></name><name><surname>Svingen</surname><given-names>P.</given-names></name><name><surname>Xiong</surname><given-names>Y.</given-names></name><name><surname>Sarmento</surname><given-names>O.F.</given-names></name><name><surname>Lomberk</surname><given-names>G.A.</given-names></name><name><surname>Urrutia</surname><given-names>R.A.</given-names></name><name><surname>Faubion</surname><given-names>W.A.</given-names></name></person-group><article-title>Kruppel-like factor KLF10 deficiency predisposes to colitis through colonic macrophage dysregulation</article-title><source>Am. J. Physiol. Gastrointest. Liver Physiol.</source><year>2015</year><volume>309</volume><fpage>G900</fpage><lpage>G909</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00309.2015</pub-id><pub-id pub-id-type="pmid">26472224</pub-id></element-citation></ref><ref id="B42-cancers-10-00161"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>N.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Yao</surname><given-names>H.</given-names></name><name><surname>Peng</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name></person-group><article-title>LncRNA OIP5-AS1 loss-induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activating PTEN/PI3K/AKT pathway in multiple myeloma</article-title><source>Cell Death Dis.</source><year>2017</year><volume>8</volume><fpage>e2975</fpage><pub-id pub-id-type="doi">10.1038/cddis.2017.358</pub-id><pub-id pub-id-type="pmid">28796257</pub-id></element-citation></ref><ref id="B43-cancers-10-00161"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iizuka</surname><given-names>K.</given-names></name><name><surname>Takeda</surname><given-names>J.</given-names></name><name><surname>Horikawa</surname><given-names>Y.</given-names></name></person-group><article-title>Kruppel-like factor-10 is directly regulated by carbohydrate response element-binding protein in rat primary hepatocytes</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2011</year><volume>412</volume><fpage>638</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2011.08.016</pub-id><pub-id pub-id-type="pmid">21856285</pub-id></element-citation></ref><ref id="B44-cancers-10-00161"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guillaumond</surname><given-names>F.</given-names></name><name><surname>Grechez-Cassiau</surname><given-names>A.</given-names></name><name><surname>Subramaniam</surname><given-names>M.</given-names></name><name><surname>Brangolo</surname><given-names>S.</given-names></name><name><surname>Peteri-Brunback</surname><given-names>B.</given-names></name><name><surname>Staels</surname><given-names>B.</given-names></name><name><surname>Fievet</surname><given-names>C.</given-names></name><name><surname>Spelsberg</surname><given-names>T.C.</given-names></name><name><surname>Delaunay</surname><given-names>F.</given-names></name><name><surname>Teboul</surname><given-names>M.</given-names></name></person-group><article-title>Kruppel-like factor kLF10 is a link between the circadian clock and metabolism in liver</article-title><source>Mol. Cell. Biol.</source><year>2010</year><volume>30</volume><fpage>3059</fpage><lpage>3070</lpage><pub-id pub-id-type="doi">10.1128/MCB.01141-09</pub-id><pub-id pub-id-type="pmid">20385766</pub-id></element-citation></ref><ref id="B45-cancers-10-00161"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>C.Z.</given-names></name><name><surname>Gavriilidis</surname><given-names>G.</given-names></name><name><surname>Asano</surname><given-names>H.</given-names></name><name><surname>Stamatoyannopoulos</surname><given-names>G.</given-names></name></person-group><article-title>Functional study of transcription factor KLF11 by targeted gene inactivation</article-title><source>Blood Cells Mol. Dis.</source><year>2005</year><volume>34</volume><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.bcmd.2004.08.027</pub-id><pub-id pub-id-type="pmid">15607700</pub-id></element-citation></ref><ref id="B46-cancers-10-00161"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramaniam</surname><given-names>M.</given-names></name><name><surname>Gorny</surname><given-names>G.</given-names></name><name><surname>Johnsen</surname><given-names>S.A.</given-names></name><name><surname>Monroe</surname><given-names>D.G.</given-names></name><name><surname>Evans</surname><given-names>G.L.</given-names></name><name><surname>Fraser</surname><given-names>D.G.</given-names></name><name><surname>Rickard</surname><given-names>D.J.</given-names></name><name><surname>Rasmussen</surname><given-names>K.</given-names></name><name><surname>van Deursen</surname><given-names>J.M.</given-names></name><name><surname>Turner</surname><given-names>R.T.</given-names></name><etal/></person-group><article-title>TIEG1 null mouse-derived osteoblasts are defective in mineralization and in support of osteoclast differentiation in vitro</article-title><source>Mol. Cell. Biol.</source><year>2005</year><volume>25</volume><fpage>1191</fpage><lpage>1199</lpage><pub-id pub-id-type="doi">10.1128/MCB.25.3.1191-1199.2005</pub-id><pub-id pub-id-type="pmid">15657444</pub-id></element-citation></ref><ref id="B47-cancers-10-00161"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zitman-Gal</surname><given-names>T.</given-names></name><name><surname>Green</surname><given-names>J.</given-names></name><name><surname>Pasmanik-Chor</surname><given-names>M.</given-names></name><name><surname>Golan</surname><given-names>E.</given-names></name><name><surname>Bernheim</surname><given-names>J.</given-names></name><name><surname>Benchetrit</surname><given-names>S.</given-names></name></person-group><article-title>Vitamin D manipulates miR-181c, miR-20b and miR-15a in human umbilical vein endothelial cells exposed to a diabetic-like environment</article-title><source>Cardiovasc. Diabetol.</source><year>2014</year><volume>13</volume><fpage>8</fpage><pub-id pub-id-type="doi">10.1186/1475-2840-13-8</pub-id><pub-id pub-id-type="pmid">24397367</pub-id></element-citation></ref><ref id="B48-cancers-10-00161"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssens</surname><given-names>K.</given-names></name><name><surname>ten Dijke</surname><given-names>P.</given-names></name><name><surname>Janssens</surname><given-names>S.</given-names></name><name><surname>Van Hul</surname><given-names>W.</given-names></name></person-group><article-title>Transforming growth factor-beta1 to the bone</article-title><source>Endocr. Rev.</source><year>2005</year><volume>26</volume><fpage>743</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1210/er.2004-0001</pub-id><pub-id pub-id-type="pmid">15901668</pub-id></element-citation></ref><ref id="B49-cancers-10-00161"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prashar</surname><given-names>P.</given-names></name><name><surname>Yadav</surname><given-names>P.S.</given-names></name><name><surname>Samarjeet</surname><given-names>F.</given-names></name><name><surname>Bandyopadhyay</surname><given-names>A.</given-names></name></person-group><article-title>Microarray meta-analysis identifies evolutionarily conserved bmp signaling targets in developing long bones</article-title><source>Dev. Biol.</source><year>2014</year><volume>389</volume><fpage>192</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2014.02.015</pub-id><pub-id pub-id-type="pmid">24583261</pub-id></element-citation></ref><ref id="B50-cancers-10-00161"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cicek</surname><given-names>M.</given-names></name><name><surname>Vrabel</surname><given-names>A.</given-names></name><name><surname>Sturchio</surname><given-names>C.</given-names></name><name><surname>Pederson</surname><given-names>L.</given-names></name><name><surname>Hawse</surname><given-names>J.R.</given-names></name><name><surname>Subramaniam</surname><given-names>M.</given-names></name><name><surname>Spelsberg</surname><given-names>T.C.</given-names></name><name><surname>Oursler</surname><given-names>M.J.</given-names></name></person-group><article-title>TGF-beta inducible early gene 1 regulates osteoclast differentiation and survival by mediating the NFATc1, Akt, and MEK/ERK signaling pathways</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e17522</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0017522</pub-id><pub-id pub-id-type="pmid">21423731</pub-id></element-citation></ref><ref id="B51-cancers-10-00161"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Shen</surname><given-names>P.</given-names></name><name><surname>Zeng</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>P.</given-names></name></person-group><article-title>TIEG1 inhibits angiotensin II-induced cardiomyocyte hypertrophy by inhibiting transcription factor GATA4</article-title><source>J. Cardiovasc. Pharmacol.</source><year>2015</year><volume>66</volume><fpage>196</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1097/FJC.0000000000000265</pub-id><pub-id pub-id-type="pmid">26252173</pub-id></element-citation></ref><ref id="B52-cancers-10-00161"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heaney</surname><given-names>A.P.</given-names></name><name><surname>Horwitz</surname><given-names>G.A.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Singson</surname><given-names>R.</given-names></name><name><surname>Melmed</surname><given-names>S.</given-names></name></person-group><article-title>Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis</article-title><source>Nat. Med.</source><year>1999</year><volume>5</volume><fpage>1317</fpage><lpage>1321</lpage><pub-id pub-id-type="doi">10.1038/15275</pub-id><pub-id pub-id-type="pmid">10546001</pub-id></element-citation></ref><ref id="B53-cancers-10-00161"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>Y.</given-names></name><name><surname>Svingen</surname><given-names>P.A.</given-names></name><name><surname>Sarmento</surname><given-names>O.O.</given-names></name><name><surname>Smyrk</surname><given-names>T.C.</given-names></name><name><surname>Dave</surname><given-names>M.</given-names></name><name><surname>Khanna</surname><given-names>S.</given-names></name><name><surname>Lomberk</surname><given-names>G.A.</given-names></name><name><surname>Urrutia</surname><given-names>R.A.</given-names></name><name><surname>Faubion</surname><given-names>W.A.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Differential coupling of kLF10 to Sin3-HDAC and PCAF regulates the inducibility of the FOXP3 gene</article-title><source>Am. J. Physiol. Regul. Integr. Comp. Physiol.</source><year>2014</year><volume>307</volume><fpage>R608</fpage><lpage>R620</lpage><pub-id pub-id-type="doi">10.1152/ajpregu.00085.2014</pub-id><pub-id pub-id-type="pmid">24944246</pub-id></element-citation></ref><ref id="B54-cancers-10-00161"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>Y.</given-names></name><name><surname>Khanna</surname><given-names>S.</given-names></name><name><surname>Grzenda</surname><given-names>A.L.</given-names></name><name><surname>Sarmento</surname><given-names>O.F.</given-names></name><name><surname>Svingen</surname><given-names>P.A.</given-names></name><name><surname>Lomberk</surname><given-names>G.A.</given-names></name><name><surname>Urrutia</surname><given-names>R.A.</given-names></name><name><surname>Faubion</surname><given-names>W.A.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Polycomb antagonizes p300/CREB-binding protein-associated factor to silence FOXP3 in a Kruppel-like factor-dependent manner</article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><fpage>34372</fpage><lpage>34385</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.325332</pub-id><pub-id pub-id-type="pmid">22896699</pub-id></element-citation></ref><ref id="B55-cancers-10-00161"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Yao</surname><given-names>L.</given-names></name><name><surname>Cui</surname><given-names>X.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Fang</surname><given-names>F.</given-names></name><name><surname>Chang</surname><given-names>Y.</given-names></name></person-group><article-title>KLF10 transcription factor regulates hepatic glucose metabolism in mice</article-title><source>Diabetologia</source><year>2017</year><volume>60</volume><fpage>2443</fpage><lpage>2452</lpage><pub-id pub-id-type="doi">10.1007/s00125-017-4412-2</pub-id><pub-id pub-id-type="pmid">28836014</pub-id></element-citation></ref><ref id="B56-cancers-10-00161"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koczulla</surname><given-names>A.R.</given-names></name><name><surname>Jonigk</surname><given-names>D.</given-names></name><name><surname>Wolf</surname><given-names>T.</given-names></name><name><surname>Herr</surname><given-names>C.</given-names></name><name><surname>Noeske</surname><given-names>S.</given-names></name><name><surname>Klepetko</surname><given-names>W.</given-names></name><name><surname>Vogelmeier</surname><given-names>C.</given-names></name><name><surname>von Neuhoff</surname><given-names>N.</given-names></name><name><surname>Rische</surname><given-names>J.</given-names></name><name><surname>Wrenger</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Kruppel-like zinc finger proteins in end-stage COPD lungs with and without severe alpha1-antitrypsin deficiency</article-title><source>Orphanet J. Rare Dis.</source><year>2012</year><volume>7</volume><fpage>29</fpage><pub-id pub-id-type="doi">10.1186/1750-1172-7-29</pub-id><pub-id pub-id-type="pmid">22621770</pub-id></element-citation></ref><ref id="B57-cancers-10-00161"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsubone</surname><given-names>T.</given-names></name><name><surname>Moran</surname><given-names>S.L.</given-names></name><name><surname>Subramaniam</surname><given-names>M.</given-names></name><name><surname>Amadio</surname><given-names>P.C.</given-names></name><name><surname>Spelsberg</surname><given-names>T.C.</given-names></name><name><surname>An</surname><given-names>K.N.</given-names></name></person-group><article-title>Effect of TGF-beta inducible early gene deficiency on flexor tendon healing</article-title><source>J. Orthop. Res.</source><year>2006</year><volume>24</volume><fpage>569</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1002/jor.20101</pub-id><pub-id pub-id-type="pmid">16463363</pub-id></element-citation></ref><ref id="B58-cancers-10-00161"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koltsova</surname><given-names>S.V.</given-names></name><name><surname>Shilov</surname><given-names>B.</given-names></name><name><surname>Birulina</surname><given-names>J.G.</given-names></name><name><surname>Akimova</surname><given-names>O.A.</given-names></name><name><surname>Haloui</surname><given-names>M.</given-names></name><name><surname>Kapilevich</surname><given-names>L.V.</given-names></name><name><surname>Gusakova</surname><given-names>S.V.</given-names></name><name><surname>Tremblay</surname><given-names>J.</given-names></name><name><surname>Hamet</surname><given-names>P.</given-names></name><name><surname>Orlov</surname><given-names>S.N.</given-names></name></person-group><article-title>Transcriptomic changes triggered by hypoxia: Evidence for HIF-1alpha-independent, [Na+]i/[K+]i-mediated, excitation-transcription coupling</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e110597</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0110597</pub-id><pub-id pub-id-type="pmid">25375852</pub-id></element-citation></ref><ref id="B59-cancers-10-00161"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bensamoun</surname><given-names>S.F.</given-names></name><name><surname>Tsubone</surname><given-names>T.</given-names></name><name><surname>Subramaniam</surname><given-names>M.</given-names></name><name><surname>Hawse</surname><given-names>J.R.</given-names></name><name><surname>Boumediene</surname><given-names>E.</given-names></name><name><surname>Spelsberg</surname><given-names>T.C.</given-names></name><name><surname>An</surname><given-names>K.N.</given-names></name><name><surname>Amadio</surname><given-names>P.C.</given-names></name></person-group><article-title>Age-dependent changes in the mechanical properties of tail tendons in TGF-beta inducible early gene-1 knockout mice</article-title><source>J. Appl. Physiol.</source><year>2006</year><volume>101</volume><fpage>1419</fpage><lpage>1424</lpage><pub-id pub-id-type="doi">10.1152/japplphysiol.00800.2005</pub-id><pub-id pub-id-type="pmid">16794021</pub-id></element-citation></ref><ref id="B60-cancers-10-00161"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bensamoun</surname><given-names>S.F.</given-names></name><name><surname>Hawse</surname><given-names>J.R.</given-names></name><name><surname>Subramaniam</surname><given-names>M.</given-names></name><name><surname>Ilharreborde</surname><given-names>B.</given-names></name><name><surname>Bassillais</surname><given-names>A.</given-names></name><name><surname>Benhamou</surname><given-names>C.L.</given-names></name><name><surname>Fraser</surname><given-names>D.G.</given-names></name><name><surname>Oursler</surname><given-names>M.J.</given-names></name><name><surname>Amadio</surname><given-names>P.C.</given-names></name><name><surname>An</surname><given-names>K.N.</given-names></name><etal/></person-group><article-title>TGFbeta inducible early gene-1 knockout mice display defects in bone strength and microarchitecture</article-title><source>Bone</source><year>2006</year><volume>39</volume><fpage>1244</fpage><lpage>1251</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2006.05.021</pub-id><pub-id pub-id-type="pmid">16876494</pub-id></element-citation></ref><ref id="B61-cancers-10-00161"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haddad</surname><given-names>O.</given-names></name><name><surname>Hawse</surname><given-names>J.R.</given-names></name><name><surname>Subramaniam</surname><given-names>M.</given-names></name><name><surname>Spelsberg</surname><given-names>T.C.</given-names></name><name><surname>Bensamoun</surname><given-names>S.F.</given-names></name></person-group><article-title>TIEG1-null osteocytes display defects in their morphology, density and surrounding bone matrix</article-title><source>J. Musculoskelet. Res.</source><year>2009</year><volume>12</volume><fpage>127</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1142/S0218957709002304</pub-id><pub-id pub-id-type="pmid">22121306</pub-id></element-citation></ref><ref id="B62-cancers-10-00161"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gumez</surname><given-names>L.</given-names></name><name><surname>Bensamoun</surname><given-names>S.F.</given-names></name><name><surname>Doucet</surname><given-names>J.</given-names></name><name><surname>Haddad</surname><given-names>O.</given-names></name><name><surname>Hawse</surname><given-names>J.R.</given-names></name><name><surname>Subramaniam</surname><given-names>M.</given-names></name><name><surname>Spelsberg</surname><given-names>T.C.</given-names></name><name><surname>Pichon</surname><given-names>C.</given-names></name></person-group><article-title>Molecular structure of tail tendon fibers in TIEG1 knockout mice using synchrotron diffraction technology</article-title><source>J. Appl. Physiol.</source><year>2010</year><volume>108</volume><fpage>1706</fpage><lpage>1710</lpage><pub-id pub-id-type="doi">10.1152/japplphysiol.00356.2010</pub-id><pub-id pub-id-type="pmid">20378701</pub-id></element-citation></ref><ref id="B63-cancers-10-00161"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawse</surname><given-names>J.R.</given-names></name><name><surname>Iwaniec</surname><given-names>U.T.</given-names></name><name><surname>Bensamoun</surname><given-names>S.F.</given-names></name><name><surname>Monroe</surname><given-names>D.G.</given-names></name><name><surname>Peters</surname><given-names>K.D.</given-names></name><name><surname>Ilharreborde</surname><given-names>B.</given-names></name><name><surname>Rajamannan</surname><given-names>N.M.</given-names></name><name><surname>Oursler</surname><given-names>M.J.</given-names></name><name><surname>Turner</surname><given-names>R.T.</given-names></name><name><surname>Spelsberg</surname><given-names>T.C.</given-names></name><etal/></person-group><article-title>TIEG-null mice display an osteopenic gender-specific phenotype</article-title><source>Bone</source><year>2008</year><volume>42</volume><fpage>1025</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2008.02.004</pub-id><pub-id pub-id-type="pmid">18396127</pub-id></element-citation></ref><ref id="B64-cancers-10-00161"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawse</surname><given-names>J.R.</given-names></name><name><surname>Pitel</surname><given-names>K.S.</given-names></name><name><surname>Cicek</surname><given-names>M.</given-names></name><name><surname>Philbrick</surname><given-names>K.A.</given-names></name><name><surname>Gingery</surname><given-names>A.</given-names></name><name><surname>Peters</surname><given-names>K.D.</given-names></name><name><surname>Syed</surname><given-names>F.A.</given-names></name><name><surname>Ingle</surname><given-names>J.N.</given-names></name><name><surname>Suman</surname><given-names>V.J.</given-names></name><name><surname>Iwaniec</surname><given-names>U.T.</given-names></name><etal/></person-group><article-title>TGFbeta inducible early gene-1 plays an important role in mediating estrogen signaling in the skeleton</article-title><source>J. Bone Miner. Res.</source><year>2014</year><volume>29</volume><fpage>1206</fpage><lpage>1216</lpage><pub-id pub-id-type="doi">10.1002/jbmr.2142</pub-id><pub-id pub-id-type="pmid">24190163</pub-id></element-citation></ref><ref id="B65-cancers-10-00161"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kammoun</surname><given-names>M.</given-names></name><name><surname>Meme</surname><given-names>S.</given-names></name><name><surname>Meme</surname><given-names>W.</given-names></name><name><surname>Subramaniam</surname><given-names>M.</given-names></name><name><surname>Hawse</surname><given-names>J.R.</given-names></name><name><surname>Canon</surname><given-names>F.</given-names></name><name><surname>Bensamoun</surname><given-names>S.F.</given-names></name></person-group><article-title>Impact of tieg1 on the structural properties of fast- and slow-twitch skeletal muscle</article-title><source>Muscle Nerve</source><year>2017</year><volume>55</volume><fpage>410</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1002/mus.25252</pub-id><pub-id pub-id-type="pmid">27421714</pub-id></element-citation></ref><ref id="B66-cancers-10-00161"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sartorelli</surname><given-names>V.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Hamamori</surname><given-names>Y.</given-names></name><name><surname>Kedes</surname><given-names>L.</given-names></name></person-group><article-title>Molecular mechanisms of myogenic coactivation by p300: Direct interaction with the activation domain of MyoD and with the MADS box of MEF2C</article-title><source>Mol. Cell. Biol.</source><year>1997</year><volume>17</volume><fpage>1010</fpage><lpage>1026</lpage><pub-id pub-id-type="doi">10.1128/MCB.17.2.1010</pub-id><pub-id pub-id-type="pmid">9001254</pub-id></element-citation></ref><ref id="B67-cancers-10-00161"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wara</surname><given-names>A.K.</given-names></name><name><surname>Foo</surname><given-names>S.</given-names></name><name><surname>Croce</surname><given-names>K.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Icli</surname><given-names>B.</given-names></name><name><surname>Tesmenitsky</surname><given-names>Y.</given-names></name><name><surname>Esen</surname><given-names>F.</given-names></name><name><surname>Lee</surname><given-names>J.S.</given-names></name><name><surname>Subramaniam</surname><given-names>M.</given-names></name><name><surname>Spelsberg</surname><given-names>T.C.</given-names></name><etal/></person-group><article-title>TGF-beta1 signaling and Kruppel-like factor 10 regulate bone marrow-derived proangiogenic cell differentiation, function, and neovascularization</article-title><source>Blood</source><year>2011</year><volume>118</volume><fpage>6450</fpage><lpage>6460</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-06-363713</pub-id><pub-id pub-id-type="pmid">21828131</pub-id></element-citation></ref><ref id="B68-cancers-10-00161"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wara</surname><given-names>A.K.</given-names></name><name><surname>Manica</surname><given-names>A.</given-names></name><name><surname>Marchini</surname><given-names>J.F.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Icli</surname><given-names>B.</given-names></name><name><surname>Tesmenitsky</surname><given-names>Y.</given-names></name><name><surname>Croce</surname><given-names>K.</given-names></name><name><surname>Feinberg</surname><given-names>M.W.</given-names></name></person-group><article-title>Bone marrow-derived Kruppel-like factor 10 controls reendothelialization in response to arterial injury</article-title><source>Arterioscler. Thromb. Vasc. Biol.</source><year>2013</year><volume>33</volume><fpage>1552</fpage><lpage>1560</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.112.300655</pub-id><pub-id pub-id-type="pmid">23685559</pub-id></element-citation></ref><ref id="B69-cancers-10-00161"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hefferan</surname><given-names>T.E.</given-names></name><name><surname>Reinholz</surname><given-names>G.G.</given-names></name><name><surname>Rickard</surname><given-names>D.J.</given-names></name><name><surname>Johnsen</surname><given-names>S.A.</given-names></name><name><surname>Waters</surname><given-names>K.M.</given-names></name><name><surname>Subramaniam</surname><given-names>M.</given-names></name><name><surname>Spelsberg</surname><given-names>T.C.</given-names></name></person-group><article-title>Overexpression of a nuclear protein, TIEG, mimics transforming growth factor-beta action in human osteoblast cells</article-title><source>J. Biol. Chem.</source><year>2000</year><volume>275</volume><fpage>20255</fpage><lpage>20259</lpage><pub-id pub-id-type="doi">10.1074/jbc.C000135200</pub-id><pub-id pub-id-type="pmid">10816551</pub-id></element-citation></ref><ref id="B70-cancers-10-00161"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engelmann</surname><given-names>D.</given-names></name><name><surname>Knoll</surname><given-names>S.</given-names></name><name><surname>Ewerth</surname><given-names>D.</given-names></name><name><surname>Steder</surname><given-names>M.</given-names></name><name><surname>Stoll</surname><given-names>A.</given-names></name><name><surname>Putzer</surname><given-names>B.M.</given-names></name></person-group><article-title>Functional interplay between E2F1 and chemotherapeutic drugs defines immediate E2F1 target genes crucial for cancer cell death</article-title><source>Cell. Mol. Life Sci.</source><year>2010</year><volume>67</volume><fpage>931</fpage><lpage>948</lpage><pub-id pub-id-type="doi">10.1007/s00018-009-0222-0</pub-id><pub-id pub-id-type="pmid">20013022</pub-id></element-citation></ref><ref id="B71-cancers-10-00161"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Partin</surname><given-names>J.V.</given-names></name><name><surname>Anglin</surname><given-names>I.E.</given-names></name><name><surname>Kyprianou</surname><given-names>N.</given-names></name></person-group><article-title>Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction</article-title><source>Br. J. Cancer</source><year>2003</year><volume>88</volume><fpage>1615</fpage><lpage>1621</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6600961</pub-id><pub-id pub-id-type="pmid">12771931</pub-id></element-citation></ref><ref id="B72-cancers-10-00161"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>G.G.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>J.F.</given-names></name><name><surname>Subramaniam</surname><given-names>M.</given-names></name><name><surname>Leung</surname><given-names>K.L.</given-names></name><name><surname>Wang</surname><given-names>S.H.</given-names></name><name><surname>Chan</surname><given-names>U.P.</given-names></name><name><surname>Spelsberg</surname><given-names>T.C.</given-names></name></person-group><article-title>15-hydroxy-eicosatetraenoic acid arrests growth of colorectal cancer cells via a peroxisome proliferator-activated receptor gamma-dependent pathway</article-title><source>Int. J. Cancer</source><year>2003</year><volume>107</volume><fpage>837</fpage><lpage>843</lpage><pub-id pub-id-type="doi">10.1002/ijc.11447</pub-id><pub-id pub-id-type="pmid">14566836</pub-id></element-citation></ref><ref id="B73-cancers-10-00161"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinholz</surname><given-names>M.M.</given-names></name><name><surname>An</surname><given-names>M.W.</given-names></name><name><surname>Johnsen</surname><given-names>S.A.</given-names></name><name><surname>Subramaniam</surname><given-names>M.</given-names></name><name><surname>Suman</surname><given-names>V.J.</given-names></name><name><surname>Ingle</surname><given-names>J.N.</given-names></name><name><surname>Roche</surname><given-names>P.C.</given-names></name><name><surname>Spelsberg</surname><given-names>T.C.</given-names></name></person-group><article-title>Differential gene expression of TGF beta inducible early gene (TIEG), SMAD7, SMAD2 and Bard1 in normal and malignant breast tissue</article-title><source>Breast Cancer Res. Treat.</source><year>2004</year><volume>86</volume><fpage>75</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1023/B:BREA.0000032926.74216.7d</pub-id><pub-id pub-id-type="pmid">15218362</pub-id></element-citation></ref><ref id="B74-cancers-10-00161"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sebestyen</surname><given-names>A.</given-names></name><name><surname>Barna</surname><given-names>G.</given-names></name><name><surname>Nagy</surname><given-names>K.</given-names></name><name><surname>Janosi</surname><given-names>J.</given-names></name><name><surname>Paku</surname><given-names>S.</given-names></name><name><surname>Kohut</surname><given-names>E.</given-names></name><name><surname>Berczi</surname><given-names>L.</given-names></name><name><surname>Mihalik</surname><given-names>R.</given-names></name><name><surname>Kopper</surname><given-names>L.</given-names></name></person-group><article-title>SMAD signal and TGFbeta induced apoptosis in human lymphoma cells</article-title><source>Cytokine</source><year>2005</year><volume>30</volume><fpage>228</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2005.01.013</pub-id><pub-id pub-id-type="pmid">15927846</pub-id></element-citation></ref><ref id="B75-cancers-10-00161"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zohrabian</surname><given-names>V.M.</given-names></name><name><surname>Nandu</surname><given-names>H.</given-names></name><name><surname>Gulati</surname><given-names>N.</given-names></name><name><surname>Khitrov</surname><given-names>G.</given-names></name><name><surname>Zhao</surname><given-names>C.</given-names></name><name><surname>Mohan</surname><given-names>A.</given-names></name><name><surname>Demattia</surname><given-names>J.</given-names></name><name><surname>Braun</surname><given-names>A.</given-names></name><name><surname>Das</surname><given-names>K.</given-names></name><name><surname>Murali</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Gene expression profiling of metastatic brain cancer</article-title><source>Oncol. Rep.</source><year>2007</year><volume>18</volume><fpage>321</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.3892/or.18.2.321</pub-id><pub-id pub-id-type="pmid">17611651</pub-id></element-citation></ref><ref id="B76-cancers-10-00161"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivanov</surname><given-names>S.V.</given-names></name><name><surname>Ivanova</surname><given-names>A.V.</given-names></name><name><surname>Salnikow</surname><given-names>K.</given-names></name><name><surname>Timofeeva</surname><given-names>O.</given-names></name><name><surname>Subramaniam</surname><given-names>M.</given-names></name><name><surname>Lerman</surname><given-names>M.I.</given-names></name></person-group><article-title>Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2008</year><volume>370</volume><fpage>536</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2008.03.066</pub-id><pub-id pub-id-type="pmid">18359287</pub-id></element-citation></ref><ref id="B77-cancers-10-00161"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Lin</surname><given-names>F.</given-names></name><name><surname>Gao</surname><given-names>S.M.</given-names></name><name><surname>Tan</surname><given-names>Y.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name></person-group><article-title>Lentivirus-mediated overexpression of TGF-beta inducible early gene 1 inhibits SW1990 pancreatic cancer cell growth</article-title><source>Cell Biol. Int.</source><year>2011</year><volume>35</volume><fpage>891</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1042/CBI20100896</pub-id><pub-id pub-id-type="pmid">21524276</pub-id></element-citation></ref><ref id="B78-cancers-10-00161"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonello</surname><given-names>D.</given-names></name><name><surname>Moore</surname><given-names>P.S.</given-names></name><name><surname>Zamboni</surname><given-names>G.</given-names></name><name><surname>Falconi</surname><given-names>M.</given-names></name><name><surname>Scarpa</surname><given-names>A.</given-names></name></person-group><article-title>Absence of mutations in the transforming growth factor-beta inducible early gene 1, TIEG1, in pancreatic cancer</article-title><source>Cancer Lett.</source><year>2002</year><volume>183</volume><fpage>179</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/S0304-3835(01)00802-3</pub-id><pub-id pub-id-type="pmid">12065093</pub-id></element-citation></ref><ref id="B79-cancers-10-00161"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Lai</surname><given-names>Y.K.</given-names></name><name><surname>Zhang</surname><given-names>J.F.</given-names></name><name><surname>Chan</surname><given-names>C.Y.</given-names></name><name><surname>Lu</surname><given-names>G.</given-names></name><name><surname>Lin</surname><given-names>M.C.</given-names></name><name><surname>He</surname><given-names>M.L.</given-names></name><name><surname>Li</surname><given-names>J.C.</given-names></name><name><surname>Kung</surname><given-names>H.F.</given-names></name></person-group><article-title>Transactivation of the TIEG1 confers growth inhibition of transforming growth factor-beta-susceptible hepatocellular carcinoma cells</article-title><source>World J. Gastroenterol.</source><year>2012</year><volume>18</volume><fpage>2035</fpage><lpage>2042</lpage><pub-id pub-id-type="doi">10.3748/wjg.v18.i17.2035</pub-id><pub-id pub-id-type="pmid">22563190</pub-id></element-citation></ref><ref id="B80-cancers-10-00161"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heo</surname><given-names>S.H.</given-names></name><name><surname>Jeong</surname><given-names>E.S.</given-names></name><name><surname>Lee</surname><given-names>K.S.</given-names></name><name><surname>Seo</surname><given-names>J.H.</given-names></name><name><surname>Lee</surname><given-names>W.K.</given-names></name><name><surname>Choi</surname><given-names>Y.K.</given-names></name></person-group><article-title>Kruppel-like factor 10 null mice exhibit lower tumor incidence and suppressed cellular proliferation activity following chemically induced liver tumorigenesis</article-title><source>Oncol. Rep.</source><year>2015</year><volume>33</volume><fpage>2037</fpage><lpage>2044</lpage><pub-id pub-id-type="doi">10.3892/or.2015.3801</pub-id><pub-id pub-id-type="pmid">25682863</pub-id></element-citation></ref><ref id="B81-cancers-10-00161"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jim</surname><given-names>H.S.</given-names></name><name><surname>Lin</surname><given-names>H.Y.</given-names></name><name><surname>Tyrer</surname><given-names>J.P.</given-names></name><name><surname>Lawrenson</surname><given-names>K.</given-names></name><name><surname>Dennis</surname><given-names>J.</given-names></name><name><surname>Chornokur</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>A.Y.</given-names></name><name><surname>Permuth-Wey</surname><given-names>J.</given-names></name><name><surname>Aben</surname><given-names>K.K.</given-names></name><etal/></person-group><article-title>Common genetic variation in circadian rhythm genes and risk of Epithelial Ovarian Cancer (EOC)</article-title><source>J. Genet. Genome Res.</source><year>2015</year><volume>2</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.23937/2378-3648/1410017</pub-id></element-citation></ref><ref id="B82-cancers-10-00161"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>V.K.</given-names></name><name><surname>Subramaniam</surname><given-names>M.</given-names></name><name><surname>Kari</surname><given-names>V.</given-names></name><name><surname>Pitel</surname><given-names>K.S.</given-names></name><name><surname>Baumgart</surname><given-names>S.J.</given-names></name><name><surname>Naylor</surname><given-names>R.M.</given-names></name><name><surname>Nagarajan</surname><given-names>S.</given-names></name><name><surname>Wegwitz</surname><given-names>F.</given-names></name><name><surname>Ellenrieder</surname><given-names>V.</given-names></name><name><surname>Hawse</surname><given-names>J.R.</given-names></name><etal/></person-group><article-title>Kruppel-like transcription factor KLF10 suppresses TGFbeta-induced epithelial-to-mesenchymal transition via a negative feedback mechanism</article-title><source>Cancer Res.</source><year>2017</year><volume>77</volume><fpage>2387</fpage><lpage>2400</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-2589</pub-id><pub-id pub-id-type="pmid">28249899</pub-id></element-citation></ref><ref id="B83-cancers-10-00161"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>K.D.</given-names></name><name><surname>Kim</surname><given-names>D.J.</given-names></name><name><surname>Lee</surname><given-names>J.E.</given-names></name><name><surname>Yun</surname><given-names>C.H.</given-names></name><name><surname>Lee</surname><given-names>W.K.</given-names></name></person-group><article-title>KLF10, transforming growth factor-beta-inducible early gene 1, acts as a tumor suppressor</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2012</year><volume>419</volume><fpage>388</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2012.02.032</pub-id><pub-id pub-id-type="pmid">22349513</pub-id></element-citation></ref><ref id="B84-cancers-10-00161"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>W.</given-names></name><name><surname>Mouzaki</surname><given-names>M.</given-names></name><name><surname>You</surname><given-names>H.</given-names></name><name><surname>Laird</surname><given-names>J.C.</given-names></name><name><surname>Mato</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>S.C.</given-names></name><name><surname>Rountree</surname><given-names>C.B.</given-names></name></person-group><article-title>CD133+ liver cancer stem cells from methionine adenosyl transferase 1A-deficient mice demonstrate resistance to transforming growth factor (TGF)-beta-induced apoptosis</article-title><source>Hepatology</source><year>2009</year><volume>49</volume><fpage>1277</fpage><lpage>1286</lpage><pub-id pub-id-type="doi">10.1002/hep.22743</pub-id><pub-id pub-id-type="pmid">19115422</pub-id></element-citation></ref><ref id="B85-cancers-10-00161"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Y.</given-names></name><name><surname>Kitisin</surname><given-names>K.</given-names></name><name><surname>Jogunoori</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Deng</surname><given-names>C.X.</given-names></name><name><surname>Mueller</surname><given-names>S.C.</given-names></name><name><surname>Ressom</surname><given-names>H.W.</given-names></name><name><surname>Rashid</surname><given-names>A.</given-names></name><name><surname>He</surname><given-names>A.R.</given-names></name><name><surname>Mendelson</surname><given-names>J.S.</given-names></name><etal/></person-group><article-title>Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2008</year><volume>105</volume><fpage>2445</fpage><lpage>2450</lpage><pub-id pub-id-type="doi">10.1073/pnas.0705395105</pub-id><pub-id pub-id-type="pmid">18263735</pub-id></element-citation></ref><ref id="B86-cancers-10-00161"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanabe</surname><given-names>A.</given-names></name><name><surname>Kurita</surname><given-names>M.</given-names></name><name><surname>Oshima</surname><given-names>K.</given-names></name><name><surname>Osada</surname><given-names>S.</given-names></name><name><surname>Nishihara</surname><given-names>T.</given-names></name><name><surname>Imagawa</surname><given-names>M.</given-names></name></person-group><article-title>Functional analysis of zinc finger proteins that bind to the silencer element in the glutathione transferase P gene</article-title><source>Biol. Pharm. Bull.</source><year>2002</year><volume>25</volume><fpage>970</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.1248/bpb.25.970</pub-id><pub-id pub-id-type="pmid">12186428</pub-id></element-citation></ref><ref id="B87-cancers-10-00161"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>V.H.</given-names></name><name><surname>Chu</surname><given-names>P.Y.</given-names></name><name><surname>Peng</surname><given-names>S.L.</given-names></name><name><surname>Mao</surname><given-names>T.L.</given-names></name><name><surname>Shan</surname><given-names>Y.S.</given-names></name><name><surname>Hsu</surname><given-names>C.F.</given-names></name><name><surname>Lin</surname><given-names>C.Y.</given-names></name><name><surname>Tsai</surname><given-names>K.K.</given-names></name><name><surname>Yu</surname><given-names>W.C.</given-names></name><name><surname>Ch&#x02019;ang</surname><given-names>H.J.</given-names></name></person-group><article-title>Kruppel-like factor 10 expression as a prognostic indicator for pancreatic adenocarcinoma</article-title><source>Am. J. Pathol.</source><year>2012</year><volume>181</volume><fpage>423</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2012.04.025</pub-id><pub-id pub-id-type="pmid">22688058</pub-id></element-citation></ref><ref id="B88-cancers-10-00161"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>M.J.</given-names></name><name><surname>Wu</surname><given-names>W.C.</given-names></name><name><surname>Chang</surname><given-names>H.W.</given-names></name><name><surname>Lai</surname><given-names>Y.T.</given-names></name><name><surname>Lin</surname><given-names>C.H.</given-names></name><name><surname>Yu</surname><given-names>W.C.</given-names></name><name><surname>Chang</surname><given-names>V.H.</given-names></name></person-group><article-title>KLF10 affects pancreatic function via the SEI-1/p21Cip1 pathway</article-title><source>Int. J. Biochem. Cell Biol.</source><year>2015</year><volume>60</volume><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2014.12.021</pub-id><pub-id pub-id-type="pmid">25578559</pub-id></element-citation></ref><ref id="B89-cancers-10-00161"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Chan</surname><given-names>C.Y.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Lin</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>M.L.</given-names></name><name><surname>Lin</surname><given-names>M.C.</given-names></name><name><surname>Yew</surname><given-names>D.T.</given-names></name><name><surname>Sung</surname><given-names>J.J.</given-names></name><name><surname>Li</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Down-regulation of stathmin is required for TGF-beta inducible early gene 1 induced growth inhibition of pancreatic cancer cells</article-title><source>Cancer Lett.</source><year>2009</year><volume>274</volume><fpage>101</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2008.09.017</pub-id><pub-id pub-id-type="pmid">18930345</pub-id></element-citation></ref><ref id="B90-cancers-10-00161"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>N.</given-names></name><name><surname>Mizumoto</surname><given-names>K.</given-names></name><name><surname>Maehara</surname><given-names>N.</given-names></name><name><surname>Shono</surname><given-names>M.</given-names></name><name><surname>Nagai</surname><given-names>E.</given-names></name><name><surname>Tanaka</surname><given-names>M.</given-names></name></person-group><article-title>Instability of chromosome 8 as an indicator of aggressive tumor phenotype in pancreatic cancer</article-title><source>J. Surg. Oncol.</source><year>2001</year><volume>76</volume><fpage>181</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1002/jso.1032</pub-id><pub-id pub-id-type="pmid">11276022</pub-id></element-citation></ref><ref id="B91-cancers-10-00161"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkov</surname><given-names>C.</given-names></name><name><surname>Plieth</surname><given-names>D.</given-names></name><name><surname>Ni</surname><given-names>T.</given-names></name><name><surname>Karmaker</surname><given-names>A.</given-names></name><name><surname>Bian</surname><given-names>A.</given-names></name><name><surname>George</surname><given-names>A.L.</given-names><suffix>Jr.</suffix></name><name><surname>Neilson</surname><given-names>E.G.</given-names></name></person-group><article-title>Transcriptional networks in epithelial-mesenchymal transition</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e25354</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0025354</pub-id><pub-id pub-id-type="pmid">21980432</pub-id></element-citation></ref><ref id="B92-cancers-10-00161"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>M.S.</given-names></name><name><surname>Chen</surname><given-names>I.C.</given-names></name><name><surname>You</surname><given-names>L.</given-names></name><name><surname>Jablons</surname><given-names>D.M.</given-names></name><name><surname>Li</surname><given-names>Y.C.</given-names></name><name><surname>Mao</surname><given-names>J.H.</given-names></name><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Lung</surname><given-names>J.H.</given-names></name><name><surname>Yang</surname><given-names>C.T.</given-names></name><name><surname>Liu</surname><given-names>S.T.</given-names></name></person-group><article-title>Knockdown of cullin 4A inhibits growth and increases chemosensitivity in lung cancer cells</article-title><source>J. Cell. Mol. Med.</source><year>2016</year><volume>20</volume><fpage>1295</fpage><lpage>1306</lpage><pub-id pub-id-type="doi">10.1111/jcmm.12811</pub-id><pub-id pub-id-type="pmid">26969027</pub-id></element-citation></ref><ref id="B93-cancers-10-00161"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>B.B.</given-names></name><name><surname>Li</surname><given-names>J.Y.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Gu</surname><given-names>S.M.</given-names></name><name><surname>Wang</surname><given-names>Q.Q.</given-names></name><name><surname>Chen</surname><given-names>J.Y.</given-names></name><name><surname>Yu</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>TIEG1 inhibits breast cancer invasion and metastasis by inhibition of epidermal growth factor receptor (EGFR) transcription and the EGFR signaling pathway</article-title><source>Mol. Cell. Biol.</source><year>2012</year><volume>32</volume><fpage>50</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1128/MCB.06152-11</pub-id><pub-id pub-id-type="pmid">22025675</pub-id></element-citation></ref><ref id="B94-cancers-10-00161"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>C.F.</given-names></name><name><surname>Sui</surname><given-names>C.L.</given-names></name><name><surname>Wu</surname><given-names>W.C.</given-names></name><name><surname>Wang</surname><given-names>J.J.</given-names></name><name><surname>Yang</surname><given-names>D.H.</given-names></name><name><surname>Chen</surname><given-names>Y.C.</given-names></name><name><surname>Yu</surname><given-names>W.C.</given-names></name><name><surname>Chang</surname><given-names>H.S.</given-names></name></person-group><article-title>KLF10 induces cell apoptosis through modulation of BI-1 expression and Ca<sup>2+</sup> homeostasis in estrogen-responding adenocarcinoma cells</article-title><source>Int. J. Biochem. Cell Biol.</source><year>2011</year><volume>43</volume><fpage>666</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2011.01.010</pub-id><pub-id pub-id-type="pmid">21262377</pub-id></element-citation></ref><ref id="B95-cancers-10-00161"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagy</surname><given-names>L.</given-names></name><name><surname>Tontonoz</surname><given-names>P.</given-names></name><name><surname>Alvarez</surname><given-names>J.G.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Evans</surname><given-names>R.M.</given-names></name></person-group><article-title>Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma</article-title><source>Cell</source><year>1998</year><volume>93</volume><fpage>229</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81574-3</pub-id><pub-id pub-id-type="pmid">9568715</pub-id></element-citation></ref><ref id="B96-cancers-10-00161"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eid</surname><given-names>M.A.</given-names></name><name><surname>Kumar</surname><given-names>M.V.</given-names></name><name><surname>Iczkowski</surname><given-names>K.A.</given-names></name><name><surname>Bostwick</surname><given-names>D.G.</given-names></name><name><surname>Tindall</surname><given-names>D.J.</given-names></name></person-group><article-title>Expression of early growth response genes in human prostate cancer</article-title><source>Cancer Res.</source><year>1998</year><volume>58</volume><fpage>2461</fpage><lpage>2468</lpage><pub-id pub-id-type="pmid">9622090</pub-id></element-citation></ref><ref id="B97-cancers-10-00161"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yono</surname><given-names>M.</given-names></name><name><surname>Mane</surname><given-names>S.M.</given-names></name><name><surname>Lin</surname><given-names>A.</given-names></name><name><surname>Weiss</surname><given-names>R.M.</given-names></name><name><surname>Latifpour</surname><given-names>J.</given-names></name></person-group><article-title>Differential effects of diabetes induced by streptozotocin and that develops spontaneously on prostate growth in Bio Breeding (BB) rats</article-title><source>Life Sci.</source><year>2008</year><volume>83</volume><fpage>192</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2008.06.006</pub-id><pub-id pub-id-type="pmid">18619471</pub-id></element-citation></ref><ref id="B98-cancers-10-00161"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barna</surname><given-names>G.</given-names></name><name><surname>Sebestyen</surname><given-names>A.</given-names></name><name><surname>Chinopoulos</surname><given-names>C.C.</given-names></name><name><surname>Nagy</surname><given-names>K.</given-names></name><name><surname>Mihalik</surname><given-names>R.</given-names></name><name><surname>Paku</surname><given-names>S.</given-names></name><name><surname>Kopper</surname><given-names>L.</given-names></name></person-group><article-title>TGF beta 1 kills lymphoma cells using mitochondrial apoptotic pathway with the help of caspase-8</article-title><source>Anticancer Res.</source><year>2002</year><volume>22</volume><fpage>3867</fpage><lpage>3872</lpage><pub-id pub-id-type="pmid">12553006</pub-id></element-citation></ref><ref id="B99-cancers-10-00161"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F.L.</given-names></name><name><surname>Zhang</surname><given-names>W.G.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Zhao</surname><given-names>W.H.</given-names></name><name><surname>Cao</surname><given-names>X.M.</given-names></name><name><surname>Chen</surname><given-names>Y.X.</given-names></name><name><surname>Tian</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>S.H.</given-names></name></person-group><article-title>Serological identification and bioinformatics analysis of immunogenic antigens in multiple myeloma</article-title><source>Cancer Immunol. Immunother.</source><year>2006</year><volume>55</volume><fpage>910</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1007/s00262-005-0074-x</pub-id><pub-id pub-id-type="pmid">16193335</pub-id></element-citation></ref><ref id="B100-cancers-10-00161"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noti</surname><given-names>J.D.</given-names></name><name><surname>Johnson</surname><given-names>A.K.</given-names></name><name><surname>Dillon</surname><given-names>J.D.</given-names></name></person-group><article-title>The zinc finger transcription factor transforming growth factor beta-inducible early gene-1 confers myeloid-specific activation of the leukocyte integrin CD11d promoter</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>26948</fpage><lpage>26958</lpage><pub-id pub-id-type="doi">10.1074/jbc.M310634200</pub-id><pub-id pub-id-type="pmid">15087465</pub-id></element-citation></ref><ref id="B101-cancers-10-00161"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noti</surname><given-names>J.D.</given-names></name><name><surname>Johnson</surname><given-names>A.K.</given-names></name><name><surname>Dillon</surname><given-names>J.D.</given-names></name></person-group><article-title>The leukocyte integrin gene CD11d is repressed by gut-enriched Kruppel-like factor 4 in myeloid cells</article-title><source>J. Biol. Chem.</source><year>2005</year><volume>280</volume><fpage>3449</fpage><lpage>3457</lpage><pub-id pub-id-type="doi">10.1074/jbc.M412627200</pub-id><pub-id pub-id-type="pmid">15561714</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="cancers-10-00161-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Phylogenic tree, common structure and zinc finger motif in SP (specificity proteins)/KLF (Kr&#x000fc;ppel-like Factors) family. (<bold>a</bold>) Phylogenic analysis based on human protein sequence from NCBI. (<bold>b</bold>) Structure of KLF family, KLFs isoforms can be divided into 3 groups based on the interaction of their N-terminal site with other proteins for transcriptional co-activators and co-repressors. Group 1 includes KLFs that contain the CtBP binding site. Group 2 includes KLFs that contain the Sin3A interaction domain. Group 3 includes KLFs that interact with acetyl-transferases. KLF15, KLF17, and KLF18 are not included in any of these groups because little is known about their protein interaction motifs and (<bold>c</bold>) multiple alignments of zinc finger domain of all family members of human Sp/KLF factors. Each protein contains three zinc fingers motifs at the C-terminus, two conserved cysteine residues and two conserved histidine residues for zinc binding are highlighted.</p></caption><graphic xlink:href="cancers-10-00161-g001a"/><graphic xlink:href="cancers-10-00161-g001b"/></fig><fig id="cancers-10-00161-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>TGF-&#x003b2; signaling and its target disease mediated by KLF10 gene. In response to TGF&#x003b2; ligand binding, KLF10 gene expression is induced in a Smad dependent manner and play a role as a tumor suppressor in many cancers. TGF&#x003b2; signaling occurs through TGF&#x003b2; receptors (T&#x003b2;RI and T&#x003b2;RII). Binding of TGF&#x003b2; ligand to T&#x003b2;RII facilitates phosphorylation of T&#x003b2;RI, which in turn phosphorylates the SMAD2 and SMAD3 proteins. After phosphorylationSmad2/Smad3 form complex with Smad4, and translocate to the nucleus to induce expression of KLF10. Subsequently, KLF10 bind to the promoters of Smad2, Smad7, and TGF-beta1, whereas the expression of the inhibitory Smad7 is blocked to disrupt the negative feedback loop. Importantly, KLF10 serves as a positive feedback loop for regulating TGF&#x003b2; signaling by inducing the expression of SMAD2 and inhibiting the expression of the inhibitory SMAD7 gene in many cancers.</p></caption><graphic xlink:href="cancers-10-00161-g002"/></fig><table-wrap id="cancers-10-00161-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">cancers-10-00161-t001_Table 1</object-id><label>Table 1</label><caption><p>SP (specificity proteins)/KLF (Kr&#x000fc;ppel-like Factors) family of transcription factors and their expression.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Previous Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Transcription Activity</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Expression Pattern</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Disease</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TGF&#x003b2; Signaling</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Sp1</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TFSP1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activator</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ubiquitous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alzheimer&#x02019;s disease (AD)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Co-activator of Smad-dependent transduction pathway in AD</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Sp2</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KIAA0048</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activator/Repressor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Sp3</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SPR-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activator/Repressor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ubiquitous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pathogenesis of keratoconus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SP1/Sp3 activities control TGF&#x003b2;RII gene</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Sp4</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SPR-1, HF1B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activator/Repressor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brain enriched</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Sp5</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ubiquitous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Sp6</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activator</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ubiquitous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Sp7</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OSX</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Osteoblastic cells</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bone cell differentiation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Sp8</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BTD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurogenic regions</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neural tube formation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Sp9</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ZNF990</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Embryonic limb morphogenesis</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>KLF1</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">E-KLF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activator</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Erythropoietic tissues (fetal liver and adult bone marrow)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anemia &#x003b2;-thalassemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>KLF2</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">L-KLF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activator</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ubiquitous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glomerular disease, atherosclerosis, vascular inflammation, cancers (leukemia, breast, colon, intestine, prostate)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits TGF-&#x003b2; signaling in atherosclerosis</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>KLF3</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BKLF, TEF-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activator/Repressor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ubiquitous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer (leukemia, cervix)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>KLF4</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G-KLF, EZF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activator/Repressor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ubiquitous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glomerular disease, IBD, acute kidney injury, liver fibrosis, heart failure, axon regeneration, different types of cancers (bladder, brain, breast, cervix, colon, intestine, esophagus, head and neck, liver, leukemia, lung, lymphoma, prostate, skin stomach, melanoma, pancreas)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell proliferation and differentiation, important target in macrophages</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>KLF5</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I-KLF, C-KLF, BTEB2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activator/Repressor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gut and epithelial tissue, Placenta</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IBD, kidney fibrosis, different types of cancers (leukemia, breast, colon, intestine, esophagus, head and neck, gastrointestinal stromal tumor, lung) pancreas, melanoma, prostate, stomach)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Proliferation, TGF&#x003b2; induced growth arrest</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>KLF6</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BCD1, COPEB, CPBP, GBF, PAC1, ST12, Zf9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activator</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ubiquitous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cardiac fibrosis, kidney fibrosis, different types of cancers (leukemia, bone, breast, brain, colon, intestine, head and neck, liver, lung, ovary, pancreas, pituitary, prostate, stomach)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell proliferation in skeletal myoblasts</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>KLF7</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U-KLF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activator</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ubiquitous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Type 2 diabetes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Satellite cell quiescence</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>KLF8</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BKLF3, ZNF741</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Repressor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ubiquitous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancers (breast, kidney, liver, ovary, prostate, stomach)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EMT</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>KLF9</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BTEB, BTEB1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activator</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ubiquitous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Demyelinating disorders, different types of cancers (brain, colon, intestine, multiple myeloma, uterus)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thyroid hormone regulation</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>KLF10</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TIEG, TIEG1, EGR&#x003b1;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activator/Repressor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ubiquitous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Angiogenesis, cardiac hypertrophy, different types of cancers (breast, kidney, pancreas, prostate)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TGF&#x003b2; induced growth inhibition</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>KLF11</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F-KLF, TIEG2, MODY7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activator/Repressor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ubiquitous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver fibrosis, type 2 diabetes, different types of cancers (leukemia, breast, colon, intestine, kidney, lung, ovary, pancreas, stomach)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TGF&#x003b2; induced growth inhibition</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>KLF12</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AP-2rep, AP2REP, HSPC122</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Repressor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brain, kidney, liver, lung</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Head and neck cancer, stomach progression of gastric cancer, salivary gland tumors, autosomal dominant polycystic kidney disease (ADPKD)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>KLF13</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BTEB3, NSLP1, RFLAT-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activator/Repressor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ubiquitous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Head and neck Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>KLF14</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BTEB5, SP6, EPFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activator/Repressor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ubiquitous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Type 2 diabetes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Transcription of TGF&#x003b2;RII</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>KLF15</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K-KLF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Repressor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ubiquitous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glomerular disease, cardiovascular disease, kidney fibrosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cardiac fibrosis</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>KLF16</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BTEB4, NSLP2, DRRF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Repressor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ubiquitous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adipose tissue expansion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Growth control mechanisms in NHK cells</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>KLF17</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ZNF393</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Repressor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Testis, brain, and bone</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancers (metastasis in breast cancer, lung, hepatocellular carcinoma (HCC), gastric cancer, papillary thyroid carcinoma)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Downstream mediator of the TGF-&#x003b2; signaling pathway, anti-metastasis</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>KLF18</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td></tr></tbody></table><table-wrap-foot><fn><p>Sp, specificity protein; Btd, buttonhead; KLF, Kruppel-like factor; EKLF, erythroid Kruppel-like factor; LKLF, lung [ED highlight&#x02014;please note, capitalization varies, please choose one form and apply consistently.] KLF; OSX, osterix; BKLF, basic KLF; GKLF gut-enriched KLF; EZF, epithelial zinc finger; BTEB2, basic transcription element binding protein 2; IKLF, intestinal-enriched KLF; CPBP, core promoter-binding protein; Zf9, zinc finger 9; GBF, GC-rich sites binding factor; UKLF, ubiquitous KLF; BTEB, basic transcription element binding protein; TIEG1, Transforming growth factor beta -inducible early gene 1; EGRaTF, early growth response a transcription factor; TIEG2, TGF-&#x003b2;-inducible early gene 2; MODY7, maturity-onset diabetes of the young 7; NSLP, novel SP1-Like Protein; AP-2rep, AP-2 repressor; BTEB3 basic transcription element-binding protein-3; FKLF2, fetal-like globin gene-activating Kruppel-like factor-2; RFLAT-1, RANTES factor of late-activated T lymphocytes 1; KKLF kidney enriched KLF; BTEB4 basic transcription element-binding protein-4; DRRF dopamine receptor regulating factor; Zfp393, zinc finger protein 393.</p></fn></table-wrap-foot></table-wrap><table-wrap id="cancers-10-00161-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">cancers-10-00161-t002_Table 2</object-id><label>Table 2</label><caption><p>KLF10 role in diseases other than cancer.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Disease</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TGF&#x003b2; Signaling</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Comments</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Bone diseases</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RANKL RUNX2 Smad2 &#x02193;<break/>Smad7 &#x02191;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Osteopenia:</bold> KLF10plays a critical role in osteoblast-mediated mineralization and osteoblast support of osteoclast differentiation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B34-cancers-10-00161" ref-type="bibr">34</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TGF-&#x003b2;1, BMP2, EGF</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Osteoblast:</bold> KLF10 plays an active role in mediating Runx2 responses following TGF&#x003b2;1 and BMP2.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B35-cancers-10-00161" ref-type="bibr">35</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Type 2 diabetes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KLF10, smad7<break/>(weakly contributes)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KLF10 variants make minor contributions to a particular genetic background that increases susceptibility to the development of T2D.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B36-cancers-10-00161" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hypertrophy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pttg1 &#x02191;<break/>(via Sp1 binding sites)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KLF10&#x02212;/&#x02212; mice develop a cardiac hypertrophic phenotype with asymmetric hypertrophy, interstitial fibrosis, and myocyte disarray.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-cancers-10-00161" ref-type="bibr">37</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immune system</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TGF-&#x003b2;1 and Foxp3 &#x02191;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Loss of KLF10 enhanced CD4+ CD25 T cell activity, which stimulated inflammation and atherosclerosis and increased peripheral proinflammatory cytokines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-cancers-10-00161" ref-type="bibr">38</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wound healing</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Smad 7 &#x02191;<break/>Smad 2, 3 &#x02193;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KLF10&#x02212;/&#x02212; mice delay wound healing. KLF10 may play a role in dermal wound healing via the TGF&#x003b2;/Smad pathway.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B39-cancers-10-00161" ref-type="bibr">39</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NASH</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TGF&#x003b2; &#x02191;<break/>ChREBP &#x02193;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Expression of KLF10 significantly increases in diet-induced NASH and ECM producing activated HSCs.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B40-cancers-10-00161" ref-type="bibr">40</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colitis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KLF10, smad2, TGF&#x003b2;RII &#x02193;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KLF10 regulates TGF&#x003b2;RII expression in murine macrophages via histone H3 modification.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B41-cancers-10-00161" ref-type="bibr">41</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hyperglycemia</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KLF10, Pgc-1&#x003b1;, Blood glucose &#x02191;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KLF10 is an important regulator of hepatic glucose metabolism in mice.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B42-cancers-10-00161" ref-type="bibr">42</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>&#x02191; increase; &#x02193; decrease.</p></fn></table-wrap-foot></table-wrap><table-wrap id="cancers-10-00161-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">cancers-10-00161-t003_Table 3</object-id><label>Table 3</label><caption><p>KLF10 role in various cancer.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cancer Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Role</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Comments</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TGF&#x003b2; Signaling</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prostate cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Suppressor</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxazosin-mediated apoptosis in prostate cancer cells involves activation of KLF10 and Smad4 mRNA levels, as well as a decrease in Smad7 mRNA expression</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Smad dependent pathway</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B71-cancers-10-00161" ref-type="bibr">71</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colorectal cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Suppressor</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KLF10 is one of the members of the signal transduction of PPAR&#x003b3; pathway</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bcl2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B72-cancers-10-00161" ref-type="bibr">72</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Suppressor</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KLF10 plays an inhibitory role in the proliferation of breast cancer. KLF10 and Smad7 in breast cancers are inversely correlated</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Smad7 &#x02191;,KLF10, Smad2, and Bard1 &#x02193;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B73-cancers-10-00161" ref-type="bibr">73</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lymphoma cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Suppressor</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The participation of Smads in TGF&#x003b2; induced apoptosis is supported by the increased expression of KLF10, which can activate the mitochondrial apoptotic pathway by increasing the intracellular level of ROS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KLF10 &#x02191;Smad 2,3 &#x02193;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B74-cancers-10-00161" ref-type="bibr">74</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brain cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Suppressor</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KLF10 is involved in apoptosis and was expressed at low levels in metastatic brain tumors.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Transactivator of TGF&#x003b2;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B75-cancers-10-00161" ref-type="bibr">75</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Leukemia cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Suppressor</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KLF10 promotes apoptosis through the mitochondrial apoptotic pathway.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BimBax &#x02191;Bcl2, Bcl-xl &#x02193;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B31-cancers-10-00161" ref-type="bibr">31</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Renal cell carcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Suppressor</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KLF10 up-regulates the expression of TGF&#x003b2;I in von Hippel-Lindau gene (VHL) deficient tumors. KLF10 is a target of VHL</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TGF&#x003b2;1 &#x02191;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B76-cancers-10-00161" ref-type="bibr">76</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Pancreatic cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Suppressor</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Overexpression of KLF10 induced by the lentivirus system inhibited pancreatic cancer cell growth in vitro and in vivo.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G1-phase arrest in vitro</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B77-cancers-10-00161" ref-type="bibr">77</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activator</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mutational screening of KLF10 in 22 pancreatic cancer cell lines revealed no alterations in expression.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No change in KLF10 expression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B78-cancers-10-00161" ref-type="bibr">78</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Hepatocellular carcinoma (HCC)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Suppressor</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Upregulation of KLF10 in the HCC cell line induces inhibition of cellular proliferation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Smad3 Smad 7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B79-cancers-10-00161" ref-type="bibr">79</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activator</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Deficiency of KLF10 suppresses cellular proliferation of hepatocytes during liver tumorigenesis through the TGF-&#x003b2;/Smad pathway</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Smad 3 TGF&#x003b2;1, TGF&#x003b2; R1 &#x02191;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B80-cancers-10-00161" ref-type="bibr">80</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ovarian cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Suppressor</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KLF10 displays strong BMAL1-dependent circadian expression; the KLF10 promoter recruits BMAL1 and is transactivated by the CLOCK/BMAL1 dimer through a conserved E-box response element.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">An interruption in Circadian genes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B81-cancers-10-00161" ref-type="bibr">81</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non&#x02013;small cell lung carcinoma (NSCLC)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Suppressor</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KLF10 suppresses TGF&#x003b2;-induced EMT in conjunction with SNAI2 and HDAC1.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KLF10 &#x02193; SNAI1 &#x02191;TGF&#x003b2;/SMAD signaling &#x02191;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B82-cancers-10-00161" ref-type="bibr">82</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Suppressor</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Loss of KLF10 leads to enhanced tumor formation and progression.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P21 &#x02191; transcriptional activation in a p53 independent manner.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B83-cancers-10-00161" ref-type="bibr">83</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple myelomas</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Suppressor</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MicroRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activation of the PTEN/PI3K/AKT pathway in multiple myeloma.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PTEN/PI3K/AKT pathway</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B42-cancers-10-00161" ref-type="bibr">42</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>&#x02191; increase; &#x02193; decrease.</p></fn></table-wrap-foot></table-wrap></floats-group></article>